Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1B (migalastat)1件: Migalastat1件: D10359 --1件: 19
2B / Phuket / 3073/2013-like virus)----1件: 53
3B-CIT and SPECT imaging----1件: 6
4B-lines SE----3件: 58, 86, 215
5B-Lymphocyte Stimulator (BLyS)----1件: 65
6B-peptide-CRM197 conjugate1件: Corynebacterium diphtheriae CRM197 protein---1件: 11
7B-STN DBS----1件: 6
8B. lactis B94----1件: 193
9B. theta----1件: 96
10B001 injection----1件: 13
11B03BB01----1件: 46
12B2-ASmedic----1件: 97
13B6, B12, L-methylfolate1件: Levomefolic acid1件: D09353 --1件: 6
14B: 2 dosis----1件: 97
15Bacille Calmette-Guerin vaccine----1件: 13
16Bacille of Calmette-Guerin----1件: 13
17Background Treatment----1件: 46
18Baclofen1件: Baclofen1件: D00241 2件: GABBR1,
GABBR2 💬		7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬7件: 2, 10, 13, 18, 65, 149, 206
19Baclofen 20 mg1件: Baclofen1件: D00241 2件: GABBR1,
GABBR2 💬		7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬1件: 13
20Baclofen ER Capsules (GRS) 10 mg1件: Baclofen1件: D00241 2件: GABBR1,
GABBR2 💬		7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬1件: 13
21Baclofen ER Capsules (GRS) 20 mg1件: Baclofen1件: D00241 2件: GABBR1,
GABBR2 💬		7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬1件: 13
22Baclofen ER Capsules (GRS) 30mg1件: Baclofen1件: D00241 2件: GABBR1,
GABBR2 💬		7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬1件: 13
23Baclofen ER Capsules (GRS) 40mg1件: Baclofen1件: D00241 2件: GABBR1,
GABBR2 💬		7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬1件: 13
24Baclofen ER Capsules (GRS) 50 mg1件: Baclofen1件: D00241 2件: GABBR1,
GABBR2 💬		7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬1件: 13
25Baclofen IR1件: Baclofen1件: D00241 2件: GABBR1,
GABBR2 💬		7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬1件: 13
26Baclofen Tablets USP1件: Baclofen1件: D00241 2件: GABBR1,
GABBR2 💬		7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬1件: 13
27Baclofen Tablets USP 10 mg1件: Baclofen1件: D00241 2件: GABBR1,
GABBR2 💬		7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬1件: 13
28BACLOFENE----1件: 10
29Bacteriophage----1件: 65
30Bacteriophage preparation----1件: 96
31Bacteriotherapy----2件: 96, 97
32Bactrim1件: Trimethoprim2件: D00145 ,
D06236 		--1件: 299
33BAF312----2件: 13, 50
34BAF312 0,25 mg tablet----1件: 13
35BAF312 0,5 mg tablet----1件: 50
36BAF312 0.25 mg----1件: 50
37BAF312 0.25 mg tablet----1件: 50
38BAF312 0.25mg tablet----1件: 50
39BAF312 0.5 mg----1件: 50
40BAF312 0.50 mg----1件: 50
41BAF312 1 mg----1件: 50
42BAF312 1 mg tablet----2件: 13, 50
43BAF312 1mg----1件: 50
44BAF312 1mg tablet----1件: 50
45BAF312 2 mg----1件: 50
46BAF312 2 mg tablet----1件: 50
47BAF312 2mg----1件: 50
48BAF312 4 mg tablet----1件: 13
49BAF312 4mg tablet----1件: 50
50BAF312 5 mg tablet----1件: 50
51BAF312 hemifumarate----2件: 13, 50
52BAF312A----1件: 13
53BAF312X----1件: 50
54Bafiertam1件: Monomethyl fumarate1件: D11492 --1件: 13
55BAL----5件: 49, 51, 84, 85, 299
56Balance1件: Isoxaflutole---8件: 6, 11, 13, 81, 113, 122, 149, 299
57Balance platform therapy1件: Isoxaflutole---1件: 13
58Balance Training1件: Isoxaflutole---1件: 6
59Balance Training with Nintendo Wii Fit1件: Isoxaflutole---1件: 6
60Ballon Pulmonary Angioplasty----1件: 88
61Balloon Pulmonary Angioplasty (BPA)----1件: 88
62Balsalazide1件: Balsalazide2件: D02715 ,
D07488 		--1件: 97
63Balsalazide Disodium1件: Balsalazide2件: D02715 ,
D07488 		--1件: 97
64Baminercept1件: Baminercept1件: D08866 1件: LTB 💬3件: Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Rheumatoid arthritis 💬4件: 13, 46, 53, 97
65Baminercept alfa1件: Baminercept1件: D08866 1件: LTB 💬3件: Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Rheumatoid arthritis 💬1件: 46
66Baminercept alfa (BG9924)1件: Baminercept1件: D08866 1件: LTB 💬3件: Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Rheumatoid arthritis 💬1件: 46
67Band----2件: 6, 97
68Bardoxolone1件: Bardoxolone1件: D09584 --7件: 66, 67, 84, 85, 86, 218, 222
69Bardoxolone methyl2件: Bardoxolone,
Bardoxolone methyl		2件: D09584 ,
D09585 		--7件: 66, 67, 84, 85, 86, 218, 222
70Bardoxolone methyl 10 mg2件: Bardoxolone,
Bardoxolone methyl		2件: D09584 ,
D09585 		--1件: 67
71Bardoxolone methyl 15 mg2件: Bardoxolone,
Bardoxolone methyl		2件: D09584 ,
D09585 		--1件: 67
72Bardoxolone methyl 20 mg2件: Bardoxolone,
Bardoxolone methyl		2件: D09584 ,
D09585 		--1件: 67
73Bardoxolone methyl 5 mg2件: Bardoxolone,
Bardoxolone methyl		2件: D09584 ,
D09585 		--1件: 67
74Bardoxolone methyl capsules2件: Bardoxolone,
Bardoxolone methyl		2件: D09584 ,
D09585 		--4件: 66, 67, 86, 222
75Bardoxolone methyl oral capsule2件: Bardoxolone,
Bardoxolone methyl		2件: D09584 ,
D09585 		--1件: 67
76BARDOXOLONE METHYL, CDDO-Me, CDDO-Methyl Ester, NSC 713200, Chemical Name: Oleana-1,9(11)-dien-28-oic acid, 2-cyano-3,12-dioxo-, methyl ester2件: Bardoxolone,
Bardoxolone methyl		2件: D09584 ,
D09585 		--1件: 86
77Bardoxolone Metile1件: Bardoxolone1件: D09584 --1件: 67
78Baricinitib----1件: 49
79Baricitinib1件: Baricitinib1件: D10308 2件: JAK1,
JAK2 💬		35件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325
80Baricitinib 2 MG1件: Baricitinib1件: D10308 2件: JAK1,
JAK2 💬		35件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 53
81Baricitinib 2 MG [Olumiant]1件: Baricitinib1件: D10308 2件: JAK1,
JAK2 💬		35件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 162
82Baricitinib Oral Tablet [Olumiant]1件: Baricitinib1件: D10308 2件: JAK1,
JAK2 💬		35件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 46
83Baricitinib treatment1件: Baricitinib1件: D10308 2件: JAK1,
JAK2 💬		35件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 46
84Baricitinib, olumiant®1件: Baricitinib1件: D10308 2件: JAK1,
JAK2 💬		35件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 46
85Barium1件: Barium---3件: 2, 19, 98
86BARNASCAN----1件: 88
87Bascial prescription plus or minus herbs depend on symptoms----1件: 97
88Baseline disease modifying therapies (DMTs)----1件: 13
89Baseline Treatment----1件: 13
90Basiliximab1件: Basiliximab1件: D03058 1件: IL2RA 💬11件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬5件: 2, 50, 97, 222, 228
91Basimglurant1件: Basimglurant1件: D10864 --1件: 158
92BASSADO----1件: 23
93BASSADO 10CPS 100MG----1件: 23
94BAT1406----1件: 271
95BAT1806----1件: 46
96BAT1806 injection----1件: 46
97BAT4406F----1件: 13
98Bavisant1件: Bavisant1件: D09870 1件: HRH3 💬1件: Neuroactive ligand-receptor interaction 💬1件: 6
99Bavisant dihydrochloride monohydrate1件: Bavisant1件: D09870 1件: HRH3 💬1件: Neuroactive ligand-receptor interaction 💬1件: 6
100BAVISANT HYDROCHLORIDE MONOHYDRATE1件: Bavisant1件: D09870 1件: HRH3 💬1件: Neuroactive ligand-receptor interaction 💬1件: 6
101Bawei Shenqi Pill----1件: 271
102BAX 111----1件: 288
103BAX111----1件: 288
104BAX930----1件: 64
105BAX930 - RECOMBINANT HUMAN ADAMTS13----1件: 64
106BAX930 or SHP655----1件: 64
107BAY 59-7939----1件: 210
108BAY 63-2521----2件: 86, 88
109BAY 63-2521 0.06 %----1件: 86
110BAY 63-2521 0.3 %----1件: 86
111BAY 63-2521 coated tablets 0.5 mg----2件: 86, 88
112BAY 63-2521 coated tablets 1 mg----2件: 86, 88
113BAY 63-2521 coated tablets 1.5 mg----2件: 86, 88
114BAY 63-2521 coated tablets 2 mg----2件: 86, 88
115BAY 63-2521 coated tablets 2.5 mg----2件: 86, 88
116BAY 63-2521 IR coated tablet 1.0 mg----1件: 88
117BAY 63-2521 IR coated tablet 1.5 mg----1件: 88
118BAY 63-2521 IR coated tablet 2.0 mg----1件: 88
119BAY 63-2521 IR coated tablet 2.5 mg----1件: 88
120BAY 63-2521 IR tablet 0.5 mg----1件: 88
121BAY 63-2521 IR tablet 1.0 mg----1件: 88
122BAY 63-2521 IR tablet 1.5 mg----1件: 88
123BAY 63-2521 IR tablet 2.0 mg----1件: 88
124BAY 63-2521 IR tablet 2.5 mg----1件: 88
125BAY 63-2521 IR tablets 0.5 mg----1件: 86
126BAY 63-2521 IR tablets 1 mg----1件: 86
127BAY 63-2521 IR tablets 1.0 mg----1件: 86
128BAY 63-2521 IR tablets 1.5 mg----1件: 86
129BAY 63-2521 IR tablets 2.0 mg----1件: 86
130BAY 63-2521 IR tablets 2.5 mg----1件: 86
131BAY 63-2521 Tablet----1件: 86
132BAY 63-2521 tablets 0.5 mg----2件: 86, 88
133BAY 63-2521 tablets 1 mg----2件: 86, 88
134BAY 63-2521 tablets 1.5 mg----2件: 86, 88
135BAY 63-2521 tablets 2 mg----2件: 86, 88
136BAY 63-2521 tablets 2.5 mg----2件: 86, 88
137BAY 79-4998----1件: 13
138BAY 85-8501----1件: 299
139BAY q 3939----1件: 299
140Bay Q 6256----1件: 86
141BAY1237592----2件: 86, 88
142BAY63-2521----3件: 51, 86, 299
143BAY85-8501----1件: 299
144BAY86-5046----1件: 13
145BAY86-5046_Interferon-beta-1b----1件: 13
146BAYQ3939----1件: 299
147Bazedoxifene1件: Bazedoxifene---1件: 13
148Bazedoxifene Acetate2件: Acetate,
Bazedoxifene		---1件: 13
149BBP-418----1件: 113
150BBP-671----2件: 245, 246
151BBR 2778----2件: 11, 13
152BBT-401-1S----1件: 97
153BBT-401-1S, Multiple doses----1件: 97
154BBT-401-1S, Single dose----1件: 97
155BBT-877, Multiple doses----1件: 85
156BBT-877, Single dose----1件: 85
157BCD-033 (interferon beta 1a)2件: Human interferon beta,
Interferon beta-1a		1件: D04554 2件: IFNAR1,
IFNAR2 💬		18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13
158BCD-054 180 mcg----1件: 13
159BCD-054 240 mcg----1件: 13
160BCD-055----2件: 46, 271
161BCD-063----1件: 13
162BCD-085----2件: 93, 271
163BCD-089----1件: 46
164BCD-089, 162 mg, s/c, q2w----1件: 46
165BCD-089, 162 mg, s/c, qw----1件: 46
166BCD-132----1件: 13
167BCD-132, 125 mg----1件: 13
168BCD-132, 500 mg----1件: 13
169BCD-148----1件: 62
170BCG----1件: 299
171BCG TICE Vaccine----1件: 299
172BCG20-0134----1件: 13
173BCX9930----3件: 62, 66, 222
174BCX9930 hydrochloride----3件: 62, 66, 222
175BCX9930 monotherapy----1件: 62
176BD----2件: 28, 46
177BDMARD----1件: 46
178BDMARD treatment----1件: 271
179BDMARD withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept)5件: Abatacept,
Adalimumab,
Etanercept,
Golimumab,
Infliximab		5件: D00742 ,
D02597 ,
D02598 ,
D03203 ,
D04358 		4件: CD80,
CD86,
LTA,
TNF 💬		73件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Autoimmune thyroid disease, C-type lectin receptor signaling pathway, Cell adhesion molecules, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 46
180Beam1件: Tricyclazole---2件: 6, 51
181BEAM Regimen----1件: 13
182Bean1件: Bean---1件: 96
183Beclometasone----1件: 97
184Beclometasone dipropionate1件: Beclomethasone dipropionate2件: D00689 ,
D07495 		1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬2件: 85, 97
185Beclomethasone dipropionate1件: Beclomethasone dipropionate2件: D00689 ,
D07495 		1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬2件: 97, 98
186Beclomethasone diproprionate----1件: 97
187Bee venom----1件: 6
188Bee venom pharmacopuncture----1件: 70
189Beetainterferoni -1a----1件: 13
190Beetroot juice----1件: 86
191BEFIRADOL----1件: 6
192Befizal----1件: 94
193BEFIZAL L.P. 400 mg, comprimé enrobé à libération prolongée----1件: 94
194Begelomab1件: Begelomab---1件: 50
195Behavior and neuropsychometric evaluations----1件: 78
196Behavioral: 50 patients will have a Free Choice between Filgotinib and anti TNF1件: Filgotinib1件: D10871 1件: JAK1 💬27件: Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 46
197Behavioral: 6 months weight resistance and balance program1件: Isoxaflutole---1件: 13
198Behavioral: 60-minutes of steady state exercise----1件: 265
199Behavioral: AbbVie Care 2.0----4件: 46, 96, 97, 271
200Behavioral: Adherence counseling----1件: 13
201Behavioral: Administration of probiotic (L. rhamnosus and L. acidophilus)1件: Lactobacillus acidophilus1件: D04349 --1件: 97
202Behavioral: Aerobic exercise----1件: 299
203Behavioral: anal dilation----1件: 291
204Behavioral: AO+VR----1件: 149
205Behavioral: Assessment of cognition----1件: 6
206Behavioral: Assessment of depression----1件: 6
207Behavioral: Assessment of disability----1件: 13
208Behavioral: Assessment of impact of MS on cognition----1件: 13
209Behavioral: Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors----1件: 6
210Behavioral: Assessment of quality of life----1件: 6
211Behavioral: Assessment of severity of ICD (impulse control disorders)----1件: 6
212Behavioral: Assessment of severity of Parkinson Disease----1件: 6
213Behavioral: Attention Control----1件: 6
214Behavioral: Augmented Reality Multi-Modal Training----1件: 6
215Behavioral: B-HIPE (Brief High Impact Preparatory Experience)----1件: 13
216Behavioral: Balance & Strengthening Exercises1件: Isoxaflutole---1件: 6
217Behavioral: Balance exercise1件: Isoxaflutole---1件: 299
218Behavioral: Balance Training1件: Isoxaflutole---2件: 6, 13
219Behavioral: BCI-FIT active querying----3件: 2, 6, 17
220Behavioral: BCI-FIT adaptive signal modeling----3件: 2, 6, 17
221Behavioral: BCI-FIT language modeling----3件: 2, 6, 17
222Behavioral: BCI-FIT multi-modal access----3件: 2, 6, 17
223Behavioral: Brisk walking and balance training1件: Isoxaflutole---1件: 6
224Behavioral: Building Better Caregivers Workshop----1件: 6
225Behavioral: Cannabis questionnaire1件: Medical Cannabis---2件: 46, 271
226Behavioral: CBT and sleep hygiene----1件: 6
227Behavioral: CHDR Monitoring Remotely (MORE)----1件: 113
228Behavioral: Clinical characteristics of AMS patients----1件: 17
229Behavioral: CO+VR----1件: 149
230Behavioral: CO-OP treatment protocol----1件: 6
231Behavioral: Cognitive and Behavioral experimental tasks----2件: 6, 127
232Behavioral: Collaborative Care (CC)----1件: 13
233Behavioral: colonic lavage----1件: 291
234Behavioral: Combined balance and brisk walking training1件: Isoxaflutole---1件: 6
235Behavioral: Conservative Measures for Orthostatic Hypotension----2件: 6, 17
236Behavioral: conservative treatment----1件: 291
237Behavioral: Control Group Typically Developing----1件: 113
238Behavioral: Dexterity----1件: 6
239Behavioral: Diet----1件: 265
240Behavioral: Diet and water adjustment1件: Water1件: D00001 --1件: 67
241Behavioral: Diet Counseling----1件: 96
242Behavioral: Dietary Counseling----1件: 46
243Behavioral: Dietary guidance----1件: 46
244Behavioral: Dietary Guidelines for Americans Diet----1件: 13
245Behavioral: Dietary recommendations----1件: 46
246Behavioral: Dual Task----1件: 6
247Behavioral: Duchenne Muscular Dystrophy group with Deflazacort1件: Deflazacort1件: D03671 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 113
248Behavioral: Duchenne Muscular Dystrophy group with Prednisone/Predisolone1件: Prednisone1件: D00473 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 113
249Behavioral: Duchenne Muscular Dystrophy group without Corticosteroids therapy----1件: 113
250Behavioral: Dyadic Psychological Support (DPS)----1件: 96
251Behavioral: ECOCAPTURE----2件: 6, 127
252Behavioral: Emotion Assessment----1件: 6
253Behavioral: Environmental Decontamination----1件: 299
254Behavioral: Exercise----3件: 6, 265, 299
255Behavioral: Exercise only----1件: 6
256Behavioral: Exercise Training----1件: 265
257Behavioral: exercise+multi-modal sensory feedback (MMSF)----1件: 6
258Behavioral: Flexibility and postural exercise----1件: 299
259Behavioral: Flexibility and strengthening exercise----1件: 6
260Behavioral: Gait and balance1件: Isoxaflutole---1件: 6
261Behavioral: gait and balance training program1件: Isoxaflutole---1件: 6
262Behavioral: General healthy eating----1件: 271
263Behavioral: Healthy age-matched controls----1件: 6
264Behavioral: heart health educational program----1件: 49
265Behavioral: High/Low Sitosterol1件: beta-Sitosterol1件: D08518 --1件: 260
266Behavioral: Hypnosis----1件: 96
267Behavioral: ICM_APATHY_TASKS----2件: 6, 127
268Behavioral: Impact of four week coaching program on dietary habits----1件: 13
269Behavioral: In-home Exercise Training----1件: 113
270Behavioral: Increased dietary intake of salmon or cod1件: Salmon, unspecified---1件: 97
271Behavioral: learning----1件: 13
272Behavioral: Levodopa or acupuncture1件: Levodopa1件: D00059 5件: DRD1,
DRD2,
DRD3,
DRD4,
DRD5 💬		11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
273Behavioral: Lifestyle----1件: 58
274Behavioral: Low Starch Diet (LSD)----1件: 271
275Behavioral: Low-Impact Exercise Control----1件: 6
276Behavioral: Medical Marijuana1件: Medical Cannabis---1件: 13
277Behavioral: meditation----1件: 13
278Behavioral: Memory----1件: 6
279Behavioral: Modified Paleolithic Elimination diet----1件: 13
280Behavioral: MOntreal Cognitive Assessment (MoCA)----1件: 17
281Behavioral: Motivational Interviewing----1件: 13
282Behavioral: Neuro-psychological Assessment----1件: 240
283Behavioral: Neurocognitive testing----1件: 19
284Behavioral: OM Meditation----1件: 6
285Behavioral: Other Academic sham tutoring----1件: 34
286Behavioral: Participant open-response writing----1件: 6
287Behavioral: Participant self-assessment surveys----1件: 6
288Behavioral: PAT sessions----1件: 6
289Behavioral: Pelvic floor muscle exercise-based behavioral therapy----1件: 6
290Behavioral: phenylalanine restricted diet1件: Phenylalanine1件: D00021 --1件: 240
291Behavioral: Phonation----1件: 6
292Behavioral: Physical Activity Together for PwMS and their CGs (PAT-MS)----1件: 13
293Behavioral: physical exam and UPDRS part III assessment----1件: 6
294Behavioral: Physical Therapy----1件: 6
295Behavioral: PICC line placement----1件: 19
296Behavioral: pre DBS patients responding to the DBS-PS scale----1件: 6
297Behavioral: Protein and calorie controlled diet----1件: 251
298Behavioral: quality of life assessment----1件: 81
299Behavioral: Questionnaire----1件: 46
300Behavioral: Questionnaires----2件: 28, 49
301Behavioral: reading tutoring intervention----1件: 34
302Behavioral: Regular exercise----1件: 113
303Behavioral: Resistance exercise----1件: 299
304Behavioral: Resistance Training----1件: 6
305Behavioral: respiratory and exercise therapy----1件: 88
306Behavioral: respiratory and exercise therapy with supplemental oxygen1件: Oxygen1件: D00003 --1件: 88
307Behavioral: Rest----1件: 6
308Behavioral: Restricted phenylalanine diet1件: Phenylalanine1件: D00021 --1件: 240
309Behavioral: Role of dopamine1件: Dopamine2件: D00633 ,
D07870 		5件: DRD1,
DRD2,
DRD3,
DRD4,
DRD5 💬		11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
310Behavioral: self massage----1件: 13
311Behavioral: Single Task----1件: 6
312Behavioral: SIT Scoring----1件: 2
313Behavioral: six-foods elimination diet----1件: 98
314Behavioral: Sleep quality and physical activity----1件: 13
315Behavioral: Smoking----1件: 13
316Behavioral: smoking and alcohol assumption1件: Ethanol4件: D00068 ,
D02798 ,
D04855 ,
D06542 		--1件: 298
317Behavioral: Speech Intelligibility Test (SIT)----1件: 2
318Behavioral: Step Tracking----1件: 13
319Behavioral: steps per day----1件: 6
320Behavioral: Strength training----1件: 6
321Behavioral: stretching----1件: 6
322Behavioral: Tai Chi----1件: 6
323Behavioral: Telephone-based Cognitive Behavioral Therapy----1件: 13
324Behavioral: The M.D. Anderson Symptom Inventory (MDASI)----1件: 28
325Behavioral: Time Restricted Olive Oil Based (TROO) Ketogenic Diet2件: Olea europaea leaf,
Olive oil		1件: D03311 --1件: 13
326Behavioral: TIP / IMPACT Plus Care Coordination----3件: 46, 96, 97
327Behavioral: Tobacco Treatment Specialist (TTS) intervention1件: Tobacco leaf---1件: 299
328Behavioral: Traditional Multi-Modal Training----1件: 6
329Behavioral: Unsupervised exercise----1件: 299
330Behavioral: Upper limb exercise----1件: 6
331Behavioral: Water Tracking1件: Water1件: D00001 --1件: 13
332Behavioral: Withings Blood Pressure Monitor1件: Methamidophos---1件: 113
333Behavioral: Withings Body+ scale----1件: 113
334Behavioral: Withings Steel HR----1件: 113
335Belantamab mafodotin1件: Belantamab mafodotin1件: D11595 10件: TNFRSF17,
TUBB,
TUBB1,
TUBB2A,
TUBB2B,
TUBB3,
TUBB4A,
TUBB4B,
TUBB6,
TUBB8 💬		12件: Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬1件: 28
336Belantamab mafodotin 1.9 mg/kg (8 weeks)1件: Belantamab mafodotin1件: D11595 10件: TNFRSF17,
TUBB,
TUBB1,
TUBB2A,
TUBB2B,
TUBB3,
TUBB4A,
TUBB4B,
TUBB6,
TUBB8 💬		12件: Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬1件: 28
337Belantamab mafodotin 1.9mg/kg or 2.5mg/kg every 4 weeks, 6 weeks or 8 weeks as determined by Part 1 recommended dosages1件: Belantamab mafodotin1件: D11595 10件: TNFRSF17,
TUBB,
TUBB1,
TUBB2A,
TUBB2B,
TUBB3,
TUBB4A,
TUBB4B,
TUBB6,
TUBB8 💬		12件: Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬1件: 28
338Belantamab mafodotin 2.5 mg/kg (4 weeks)1件: Belantamab mafodotin1件: D11595 10件: TNFRSF17,
TUBB,
TUBB1,
TUBB2A,
TUBB2B,
TUBB3,
TUBB4A,
TUBB4B,
TUBB6,
TUBB8 💬		12件: Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬1件: 28
339Belantamab mafodotin 2.5 mg/kg (6 weeks)1件: Belantamab mafodotin1件: D11595 10件: TNFRSF17,
TUBB,
TUBB1,
TUBB2A,
TUBB2B,
TUBB3,
TUBB4A,
TUBB4B,
TUBB6,
TUBB8 💬		12件: Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬1件: 28
340Belantamab mafodotin 2.5 mg/kg (8 weeks)1件: Belantamab mafodotin1件: D11595 10件: TNFRSF17,
TUBB,
TUBB1,
TUBB2A,
TUBB2B,
TUBB3,
TUBB4A,
TUBB4B,
TUBB6,
TUBB8 💬		12件: Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬1件: 28
341Belatacept1件: Belatacept1件: D03222 2件: CD80,
CD86 💬		12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis 💬1件: 46
342Belcesiran----1件: 231
343BELIMUMAB1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬12件: 11, 13, 43, 44, 46, 49, 51, 53, 66, 222, 296, 300
344Belimumab 1 mg/kg1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬2件: 46, 49
345Belimumab 10 mg1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬1件: 222
346Belimumab 10 mg/kg1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬3件: 43, 46, 49
347Belimumab 10 mg/kg plus standard therapy1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬1件: 49
348Belimumab 100 mg SC1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬1件: 49
349Belimumab 10mg/kg1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬1件: 49
350Belimumab 200 mg SC1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬1件: 49
351Belimumab 200 mg/mL1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬1件: 49
352Belimumab 4 mg/kg1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬2件: 46, 49
353Belimumab autoinjector1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬1件: 49
354Belimumab for IV1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬1件: 49
355Belimumab for SC1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬1件: 49
356Belimumab Injection1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬1件: 49
357Belimumab Injection [Benlysta]1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬1件: 49
358Belimumab or benlysta1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬1件: 49
359Belimumab plus Early Vaccination1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬1件: 49
360Belimumab plus Late Vaccination1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬1件: 49
361Beloranib1件: Beloranib---1件: 193
362Belumosudil1件: Belumosudil1件: D11815 1件: ROCK2 💬21件: Axon guidance, Chemokine signaling pathway, Focal adhesion, Human cytomegalovirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Platelet activation, Proteoglycans in cancer, Regulation of actin cytoskeleton, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Tight junction, Vascular smooth muscle contraction, Wnt signaling pathway, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 51
363Belumosudil (KD025)1件: Belumosudil1件: D11815 1件: ROCK2 💬21件: Axon guidance, Chemokine signaling pathway, Focal adhesion, Human cytomegalovirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Platelet activation, Proteoglycans in cancer, Regulation of actin cytoskeleton, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Tight junction, Vascular smooth muscle contraction, Wnt signaling pathway, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 51
364BEN-2001----1件: 6
365Benazepril1件: Benazepril2件: D00620 ,
D07499 		1件: ACE 💬6件: Chagas disease, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Renin secretion, Renin-angiotensin system 💬4件: 49, 57, 218, 224
366Benazepril hydrochloride 10 milligram (mg) Tab1件: Benazepril2件: D00620 ,
D07499 		1件: ACE 💬6件: Chagas disease, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Renin secretion, Renin-angiotensin system 💬1件: 218
367Benazepril Hydrochloride Tablets1件: Benazepril2件: D00620 ,
D07499 		1件: ACE 💬6件: Chagas disease, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Renin secretion, Renin-angiotensin system 💬1件: 224
368Benazepril Pill1件: Benazepril2件: D00620 ,
D07499 		1件: ACE 💬6件: Chagas disease, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Renin secretion, Renin-angiotensin system 💬1件: 49
369Benazepril, Valsartan and Fluvastatin3件: Benazepril,
Fluvastatin,
Valsartan		5件: D00400 ,
D00620 ,
D00892 ,
D07499 ,
D07983 		3件: ACE,
AGTR1,
HMGCR 💬		22件: AGE-RAGE signaling pathway in diabetic complications, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Bile secretion, Calcium signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Terpenoid backbone biosynthesis, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 218
370Bendamustine1件: Bendamustine1件: D07501 --2件: 28, 61
371BENDAMUSTINE HYDROCHLORIDE1件: Bendamustine1件: D07501 --1件: 61
372Bendamustine, Rituximab2件: Bendamustine,
Rituximab		2件: D02994 ,
D07501 		1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 61
373BENDROFLUMETHIAZIDE1件: Bendroflumethiazide1件: D00650 1件: SLC12A3 💬-1件: 67
374Benepali1件: Etanercept1件: D00742 2件: LTA,
TNF 💬		67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 46
375Benerva----1件: 8
376Benlysta1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬5件: 43, 49, 53, 66, 222
377Benlysta (belimumab)1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬4件: 11, 49, 53, 222
378BENLYSTA - 120 MG - POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) 120 MG 1 FLACONCINO1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬1件: 53
379Benlysta 400 mg powder for concentrate for solution for infusion1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬2件: 43, 49
380Benlysta 400 mg powder for concentrate for solution for infusions1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬1件: 49
381Benlysta 400mg polvere per concentrato per soluzione per infusione1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬1件: 43
382BENLYSTA? (belimumab)1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬1件: 49
383Benlysta®1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬2件: 49, 222
384BENLYSTA® (belimumab)1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬3件: 11, 66, 222
385BENLYSTA™ (belimumab)1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬1件: 49
386Benralizumab1件: Benralizumab1件: D09874 1件: IL5RA 💬4件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬5件: 44, 45, 98, 162, 299
387BENSERAZIDE1件: Benserazide1件: D03082 1件: DDC 💬9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬1件: 6
388BENSERAZIDE HYDROCHLORIDE1件: Benserazide1件: D03082 1件: DDC 💬9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬1件: 6
389Benzbromaron----1件: 86
390Benzbromaron AL----1件: 86
391BENZBROMARONE1件: Benzbromarone1件: D01056 1件: SLC22A12 💬-1件: 86
392Benzimidazole1件: Benzimidazole---1件: 46
393Benzimidazole,5-methoxy-2-[[(4-methoxy- 3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1 H-benzimidazole1件: Benzimidazole---1件: 46
394Benzimidazole,5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1 H-benzimidazole1件: Benzimidazole---1件: 46
395Benznidazole1件: Benznidazole1件: D02489 --1件: 65
396Benzofuran1件: Benzofuran---1件: 6
397Benzoic acid1件: Benzoic acid1件: D00038 --1件: 51
398Benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala)2件: Alanine,
Tyrosine		2件: D00012 ,
D00022 		--1件: 298
399Bepranemab----1件: 5
400Berachin----1件: 6
401Beraprost1件: Beraprost1件: D02720 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
402Beraprost Sodium1件: Beraprost1件: D02720 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
403Beraprost Sodium 314d Modified Release Tablets1件: Beraprost1件: D02720 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
404Beraprost Sodium Modified Release1件: Beraprost1件: D02720 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
405Berberine1件: Berberine---2件: 97, 265
406Berberine Chloride2件: Berberine,
Chloride ion		---1件: 97
407BERMEKIMAB1件: Bermekimab1件: D11253 1件: IL1A 💬21件: AGE-RAGE signaling pathway in diabetic complications, Alzheimer disease, Cellular senescence, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Inflammatory bowel disease, Influenza A, Leishmaniasis, MAPK signaling pathway, Measles, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Tuberculosis, Type I diabetes mellitus 💬1件: 51
408Bertilimumab----2件: 97, 162
409Best Available Therapy (BAT)----1件: 13
410Best Medical Treatment----1件: 6
411Best médical treatment----1件: 6
412Best Supportive Care (BSC)----1件: 331
413Beta carotene1件: Beta carotene1件: D03101 --1件: 96
414Beta carotene from Dunaliella algae1件: Beta carotene1件: D03101 --1件: 96
415Beta Hydroxybutyrate----1件: 2
416Beta-1,3/1,6-D-Glucan----1件: 97
417Beta-1b interferoni----1件: 13
418Beta-Adrenergic cocktail----1件: 299
419Beta-Alanine2件: Alanine,
beta-Alanine		2件: D00012 ,
D07561 		--1件: 13
420Beta-alanine supplementation2件: Alanine,
beta-Alanine		2件: D00012 ,
D07561 		--1件: 13
421Beta-Carotene1件: Beta carotene1件: D03101 --1件: 13
422Beta-cyclodextrin1件: Betadex1件: D02401 --1件: 19
423Beta-Galactosidase1件: Tilactase1件: D03348 --1件: 19
424Beta-hydroxybuturate esters----1件: 256
425Beta-Interferon----1件: 13
426Beta-Mercaptoethylamine1件: Cysteamine2件: D03634 ,
D03635 		--1件: 19
427Beta-mercaptoethylamine Hydrochloride & 2-aminoethanethiol Hydrochloride1件: Cysteamine2件: D03634 ,
D03635 		--1件: 19
428BETACAROTENE1件: Beta carotene1件: D03101 --1件: 13
429BETACONNECT----1件: 13
430Betaconnect auto-injector----1件: 13
431BETACONNECT auto-injector.----1件: 13
432Betaconnect Autoinjector----1件: 13
433BETACONNECT device----1件: 13
434BETAFERON1件: Interferon beta-1b1件: D00746 2件: IFNAR1,
IFNAR2 💬		18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13
435BETAFERON - 15 FLACONCINI 0.25 MG + 15 FLACONCINI 2 ML1件: Interferon beta-1b1件: D00746 2件: IFNAR1,
IFNAR2 💬		18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13
436BETAFERON 250 mcg1件: Interferon beta-1b1件: D00746 2件: IFNAR1,
IFNAR2 💬		18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13
437Betaferon 250 microgram/ml1件: Interferon beta-1b1件: D00746 2件: IFNAR1,
IFNAR2 💬		18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13
438Betaferon 250 microgram/ml, powder and solvent for solution for injection1件: Interferon beta-1b1件: D00746 2件: IFNAR1,
IFNAR2 💬		18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13
439Betaferon 250 microgram/mL, powder and solvent for solution for injection.1件: Interferon beta-1b1件: D00746 2件: IFNAR1,
IFNAR2 💬		18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13
440Betaferon 250 microgramos----1件: 13
441Betaferon 250mcg----1件: 13
442Betaferon 250µg1件: Interferon beta-1b1件: D00746 2件: IFNAR1,
IFNAR2 💬		18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13
443BETAFERON 500 mcg1件: Interferon beta-1b1件: D00746 2件: IFNAR1,
IFNAR2 💬		18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13
444Betaferon 500 µg----1件: 13
445Betaferon 500mcg----1件: 13
446Betaferon 500µg1件: Interferon beta-1b1件: D00746 2件: IFNAR1,
IFNAR2 💬		18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13
447BETAFERON SC 15F 0,25MG 15SIR1件: Interferon beta-1b1件: D00746 2件: IFNAR1,
IFNAR2 💬		18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13
448BETAFERON*15CONFEZ 0,25MG/ML+1件: Interferon beta-1b1件: D00746 2件: IFNAR1,
IFNAR2 💬		18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13
449Betaferon, BAY86-5046----1件: 13
450Betaferon/Betaseron----1件: 13
451Betaferon®1件: Interferon beta-1b1件: D00746 2件: IFNAR1,
IFNAR2 💬		18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13
452BETAFERON® (interferon beta-1b)2件: Human interferon beta,
Interferon beta-1b		1件: D00746 2件: IFNAR1,
IFNAR2 💬		18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13
453Betaine1件: Betaine1件: D07523 --2件: 201, 337
454Betaloc ZOK 100, 95 mg----1件: 113
455Betaloc ZOK 25, 23,75 mg----1件: 113
456Betamethasone1件: Betamethasone7件: D00244 ,
D00972 ,
D01357 ,
D01402 ,
D01637 ,
D02032 ,
D02286 		1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬7件: 2, 28, 46, 83, 90, 96, 235
457BETAMETHASONE ACIBUTATE1件: Betamethasone7件: D00244 ,
D00972 ,
D01357 ,
D01402 ,
D01637 ,
D02032 ,
D02286 		1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 46
458Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days3件: Acetate,
Betamethasone,
Phosphate ion		7件: D00244 ,
D00972 ,
D01357 ,
D01402 ,
D01637 ,
D02032 ,
D02286 		1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 2
459Betaquik MCT supplement----1件: 6
460Betaseron1件: Interferon beta-1b1件: D00746 2件: IFNAR1,
IFNAR2 💬		18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13
461Betaseron (Interferon beta-1b, BAY86-5046)2件: Human interferon beta,
Interferon beta-1b		1件: D00746 2件: IFNAR1,
IFNAR2 💬		18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13
462Betaseron (Interferon beta-1b, BAY86-5046), Bayer HealthCare AG2件: Human interferon beta,
Interferon beta-1b		1件: D00746 2件: IFNAR1,
IFNAR2 💬		18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13
463Bethanechol1件: Bethanechol1件: D01000 5件: CHRM1,
CHRM2,
CHRM3,
CHRM4,
CHRM5 💬		13件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬1件: 98
464Bethkis----1件: 299
465Better----2件: 6, 13
466Bevacizumab1件: Bevacizumab1件: D06409 1件: VEGFA 💬24件: AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, Calcium signaling pathway, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway 💬9件: 13, 34, 85, 86, 87, 89, 227, 280, 331
467Bevacizumab (Avastin) and Imatinib Mesylate (Gleevec)2件: Bevacizumab,
Imatinib		3件: D01441 ,
D06409 ,
D08066 		4件: ABL1,
KIT,
PDGFRA,
VEGFA 💬		45件: AGE-RAGE signaling pathway in diabetic complications, Acute myeloid leukemia, Axon guidance, Bladder cancer, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Fluid shear stress and atherosclerosis, Focal adhesion, Gap junction, Glioma, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pancreatic cancer, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway, Viral myocarditis 💬1件: 87
468Bevacizumab (Genitical Recombination)1件: Bevacizumab1件: D06409 1件: VEGFA 💬24件: AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, Calcium signaling pathway, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway 💬1件: 34
469BEVACIZUMAB ZIRCONIUM ZR-892件: Bevacizumab,
Bevacizumab zirconium Zr-89		1件: D06409 1件: VEGFA 💬24件: AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, Calcium signaling pathway, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway 💬1件: 34
470Bevacuzimab spray----1件: 227
471Bevantolol1件: Bevantolol---1件: 8
472BEVANTOLOL HYDROCHLORIDE1件: Bevantolol---1件: 8
473Bexarotene1件: Bexarotene1件: D03106 3件: RXRA,
RXRB,
RXRG 💬		17件: Adipocytokine signaling pathway, Bile secretion, Chemical carcinogenesis - receptor activation, Gastric cancer, Hepatitis C, Lipid and atherosclerosis, Non-alcoholic fatty liver disease, Non-small cell lung cancer, PI3K-Akt signaling pathway, PPAR signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Thyroid cancer, Thyroid hormone signaling pathway, Transcriptional misregulation in cancer 💬2件: 13, 75
474Bexsero1件: Neisseria meningitidis serogroup b nhba fusion protein antigen---6件: 11, 13, 61, 62, 66, 222
475BEXSERO - SOSPENSIONE INIETTABILE - USO INTRAMUSCOLARE - SIRINGA P1件: Neisseria meningitidis serogroup b nhba fusion protein antigen---1件: 62
476BEXSERO - SOSPENSIONE INIETTABILE - USO INTRAMUSCOLARE - SIRINGA PRERIEMPITA (VETRO) - 0.5ML - 1 SIRINGA PRERIEMPITA CON AGO1件: Neisseria meningitidis serogroup b nhba fusion protein antigen---1件: 66
477BEXSERO – Sospensione iniettabile – Siringa preriempita1件: Neisseria meningitidis serogroup b nhba fusion protein antigen---2件: 61, 62
478Bezafibrat----1件: 93
479Bezafibrat Genericon retard 400 mg----1件: 93
480Bezafibrate1件: Bezafibrate1件: D01366 1件: PPARA 💬10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬7件: 20, 93, 94, 160, 296, 316, 324
481Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy2件: Bezafibrate,
Ursodeoxycholic acid		2件: D00734 ,
D01366 		2件: NR1H4,
PPARA 💬		11件: Adipocytokine signaling pathway, Alcoholic liver disease, Bile secretion, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 94
482Bezafibrate (drug)1件: Bezafibrate1件: D01366 1件: PPARA 💬10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 316
483Bezafibrate (INN 3968)1件: Bezafibrate1件: D01366 1件: PPARA 💬10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 324
484Bezafibrate 100 MG1件: Bezafibrate1件: D01366 1件: PPARA 💬10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 93
485Bezafibrate 200 MG1件: Bezafibrate1件: D01366 1件: PPARA 💬10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 93
486Bezafibrate 200 MG Oral Tablet1件: Bezafibrate1件: D01366 1件: PPARA 💬10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 93
487Bezafibrate 400 MG1件: Bezafibrate1件: D01366 1件: PPARA 💬10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 93
488Bezafibrate IR1件: Bezafibrate1件: D01366 1件: PPARA 💬10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 93
489Bezafibrate SR1件: Bezafibrate1件: D01366 1件: PPARA 💬10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 93
490Bezafibrate, Beza, BZF, Bezalip1件: Bezafibrate1件: D01366 1件: PPARA 💬10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 93
491Bezafibrate, Beza, BZF, Bezalip mono1件: Bezafibrate1件: D01366 1件: PPARA 💬10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 93
492Bezalip----3件: 93, 94, 160
493Bezalip mono----1件: 93
494Bezalip Retard----1件: 160
495Bezlotoxumab1件: Bezlotoxumab1件: D10453 --2件: 96, 97
496BF 2.649----1件: 6
497BF 2.649 10 mg----1件: 6
498BF 2.649 20 mg----1件: 6
499BF 2.649 40 mg----1件: 6
500BF 2.649 5 mg----1件: 6
501BF2.649----1件: 6
502BF2.649 (Pitolisant)1件: Pitolisant1件: D10749 1件: HRH3 💬1件: Neuroactive ligand-receptor interaction 💬1件: 6
503BFAHF-2----1件: 96
504BFGF1件: Basic Fibroblast Growth Factor---1件: 56
505BG-12 120----1件: 13
506BG00002----1件: 13
507BG00002 (natalizumab)1件: Natalizumab1件: D06886 1件: ITGA4 💬14件: Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬1件: 13
508BG00002-E (natalizumab high titer)1件: Natalizumab1件: D06886 1件: ITGA4 💬14件: Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬1件: 13
509BG00011----1件: 85
510BG00012----2件: 13, 46
511BG00012 (DMF)----1件: 13
512BG00012 (DMF) (Tecfidera®.)----1件: 13
513BG0002 (natalizumab)1件: Natalizumab1件: D06886 1件: ITGA4 💬14件: Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬1件: 13
514BG9418 (interferon beta 1-a)2件: Human interferon beta,
Interferon beta-1a		1件: D04554 2件: IFNAR1,
IFNAR2 💬		18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13
515BG9418 (interferon beta-1a)2件: Human interferon beta,
Interferon beta-1a		1件: D04554 2件: IFNAR1,
IFNAR2 💬		18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬2件: 13, 97
516BG9924----2件: 46, 97
517BGC20-0134----1件: 13
518BGG492----1件: 13
519BGJ398----1件: 238
520BGJ398 (also known as BBP-831)----1件: 276
521BGP-014----1件: 97
522BGP-014 Capsules----1件: 97
523BGX-0214----1件: 46
524BH4----5件: 51, 86, 124, 240, 299
525BH4 20mg----1件: 299
526BH4 5mg----1件: 299
527BHP001----1件: 19
528BHT-3009----1件: 13
529BHT-3009 0.5 mg----1件: 13
530BHT-3009 1.5 mg----1件: 13
531BHT-3009-01----1件: 13
532BHV-0223----1件: 2
533BHV-3241----1件: 17
534BHV-4157----1件: 17
535BI 1015550----1件: 85
536BI 1265162----1件: 299
537BI 1265162 10 µg----1件: 299
538BI 1265162 100 µg----1件: 299
539BI 1265162 25 µg----1件: 299
540BI 1265162 50 µg----1件: 299
541BI 1323495----1件: 299
542BI 443651----1件: 299
543BI 655064----1件: 46
544BI 655064 high dose----1件: 46
545BI 655064 low dose----1件: 46
546BI 655064 medium dose----1件: 46
547BI 655066----2件: 96, 271
548BI 655066 10 mg/ml----1件: 96
549BI 655066 90 mg/ml----2件: 96, 271
550BI 655130----3件: 37, 96, 97
551BI 695500----1件: 46
552BI 695501----2件: 46, 96
553BI 695501 Autoinjector----1件: 46
554BI 695501 Prefilled syringe----1件: 46
555BI 705564----1件: 49
556BI 706321----1件: 96
557BI 730357----1件: 271
558BI 764198----1件: 222
559BI-Sifrol®----1件: 6
560BI655130----1件: 37
561BIA1件: BIA---2件: 6, 86
562BIA 3-2021件: BIA---1件: 6
563BIA 3-202 (200 mg)1件: BIA---1件: 6
564BIA 5-10581件: BIA---1件: 86
565BIA 6-5121件: BIA---1件: 6
566BIA 6-512 100 mg1件: BIA---1件: 6
567BIA 6-512 100 mg dose1件: BIA---1件: 6
568BIA 6-512 200 mg dose1件: BIA---1件: 6
569BIA 6-512 25 mg1件: BIA---1件: 6
570BIA 6-512 25 mg dose1件: BIA---1件: 6
571BIA 6-512 400 mg1件: BIA---1件: 6
572BIA 6-512 50 mg dose1件: BIA---1件: 6
573BIA 9-10671件: BIA---1件: 6
574BIA 9-1067 (test)1件: BIA---1件: 6
575BIA 9-1067 15 mg1件: BIA---1件: 6
576BIA 9-1067 25 mg1件: BIA---1件: 6
577BIA 9-1067 30 mg1件: BIA---1件: 6
578BIA 9-1067 5 mg1件: BIA---1件: 6
579BIA 9-1067 micronized1件: BIA---1件: 6
580BIA 9-1067 non-micronized1件: BIA---1件: 6
581BIA-5-10581件: BIA---1件: 86
582BIAP----2件: 46, 97
583Biaxin ( clarithromycin)1件: Clarithromycin1件: D00276 --1件: 299
584BIBF 1120----2件: 51, 85
585BIBF 1120 ES----1件: 85
586BIBF1120----1件: 85
587BIBR 796 BS----1件: 46
588BIBR 796 BS, 20 mg----1件: 96
589BIBR 796 BS, 5 mg----1件: 96
590Bicain spinal----1件: 46
591Bicarbonate Ringer's solution----1件: 296
592Bif195 capsules----1件: 96
593Bifico----1件: 291
594Bifidobacterium breve1件: Bifidobacterium breve---1件: 97
595Bifidobacterium infantis1件: Bifidobacterium longum infantis---2件: 96, 97
596Bifidobacterium infantis 356241件: Bifidobacterium longum infantis---2件: 96, 97
597BIIB 017----1件: 13
598BIIB014----1件: 6
599BIIB017----1件: 13
600BIIB017 (Peginterferon beta-1a)1件: Peginterferon beta-1a1件: D10483 2件: IFNAR1,
IFNAR2 💬		18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13
601BIIB017 (peginterferon beta-1a) Autoinjector1件: Peginterferon beta-1a1件: D10483 2件: IFNAR1,
IFNAR2 💬		18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13
602BIIB017 (peginterferon beta-1a) Pre-filled syringe (PFS)1件: Peginterferon beta-1a1件: D10483 2件: IFNAR1,
IFNAR2 💬		18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13
603BIIB019----1件: 13
604BIIB019 (Daclizumab High Yield Process)1件: Daclizumab1件: D03639 1件: IL2RA 💬11件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 13
605BIIB019 (Daclizumab)1件: Daclizumab1件: D03639 1件: IL2RA 💬11件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 13
606BIIB023----1件: 46
607BIIB033----1件: 13
608BIIB033 (ANTI-LINGO)----1件: 13
609BIIB033 (ANTI-LINGO) - EV Substance Code SUB118957----1件: 13
610BIIB033 (opicinumab)1件: Opicinumab1件: D11767 1件: LINGO1 💬-1件: 13
611BIIB041----1件: 13
612BIIB041 (fampridine)1件: Dalfampridine1件: D04127 4件: KCNA4,
KCNC3,
KCND2,
KCND3 💬		4件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬1件: 13
613BIIB041 (Fampridine-SR)1件: Dalfampridine1件: D04127 4件: KCNA4,
KCNC3,
KCND2,
KCND3 💬		4件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬1件: 13
614BIIB041 (PR Fampridine)1件: Dalfampridine1件: D04127 4件: KCNA4,
KCNC3,
KCND2,
KCND3 💬		4件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬1件: 13
615BIIB050 / KNS-760704----1件: 2
616BIIB050/KNS-760704----1件: 2
617BIIB054----1件: 6
618BIIB057----1件: 46
619BIIB059----1件: 49
620BIIB061----1件: 13
621BIIB067----1件: 2
622BIIB067 (ISIS666853)----1件: 2
623BIIB067 (Tofersen)1件: Tofersen1件: D11811 1件: SOD1 💬8件: Amyotrophic lateral sclerosis, Chemical carcinogenesis - reactive oxygen species, Huntington disease, Longevity regulating pathway - multiple species, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Peroxisome, Prion disease 💬1件: 2
624BIIB078----1件: 2
625BIIB092----3件: 5, 7, 127
626BIIB094----1件: 6
627BIIB100----1件: 2
628BIIB101----1件: 17
629BIIB105----1件: 2
630BIIB112----1件: 90
631BIIB133----1件: 13
632BIIL 283 BS (Amelubent)----1件: 299
633BIIL 284 BS high dose----1件: 46
634BIIL 284 BS low dose----1件: 46
635BIIL 284 BS medium dose----1件: 46
636BIIL 284 BS, high dose----1件: 299
637BIIL 284 BS, high dose, adult patients----1件: 299
638BIIL 284 BS, high dose, pediatric patients----1件: 299
639BIIL 284 BS, low dose----1件: 299
640BIIL 284 BS, low dose, adult patients----1件: 299
641BIIL 284 BS, low dose, pediatric patients----1件: 299
642BIIL 284 BS, medium dose, adult patients----1件: 299
643BIIL 284 BS, medium dose, pediatric patients----1件: 299
644Biklin----1件: 299
645Bilateral transforaminal epidural steroid injections----1件: 70
646Biliary stent----1件: 300
647BIM 23014----1件: 67
648Bimagrumab1件: Bimagrumab1件: D10620 2件: ACVR2A,
ACVR2B 💬		4件: Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Signaling pathways regulating pluripotency of stem cells, TGF-beta signaling pathway 💬1件: 15
649BIMEKIZUMAB1件: Bimekizumab1件: D11550 2件: IL17A,
IL17F 💬		6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬3件: 46, 97, 271
650Binimetinib1件: Binimetinib1件: D10604 2件: MAP2K1,
MAP2K2 💬		89件: Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, B cell receptor signaling pathway, Bladder cancer, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, VEGF signaling pathway, Vascular smooth muscle contraction, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬1件: 34
651BINOCRIT*1SIR 40000UI/1ML1件: Erythropoietin1件: D03231 1件: EPOR 💬5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬1件: 18
652Binyrebarkhormon----1件: 46
653Binyrebsrkhormon----1件: 46
654Bio-25 probiotic----1件: 299
655Bio-enhanced Curcumin Soft Gelatin Capsule2件: Curcumin,
Gelatin		2件: D00115 ,
D06892 		--1件: 97
656BIO101----1件: 113
657Bioactive Glass-Ceramic Spacer----1件: 70
658Biocarn----1件: 3
659Biochemical analysis of different bone markers.----1件: 172
660Biodmards----1件: 46
661Biofluid samplings----1件: 6
662Biologic Agents----1件: 46
663Biologic DMARD----2件: 46, 271
664Biologic TNFi----1件: 46
665Biologic/targeted therapy----1件: 46
666Biologic: IC14 (monoclonal antibody against human CD14)----1件: 2
667Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL)1件: Human immunoglobulin G---1件: 14
668Biological agents----1件: 46
669Biological assays----1件: 19
670Biological assessment----1件: 61
671Biological disease-modifying antirheumatic drugs (bDMARDs)----1件: 46
672Biological DMARDs----2件: 86, 107
673Biological Drug----2件: 46, 97
674Biological samples----1件: 13
675Biological sampling----1件: 65
676Biological samplings----1件: 96
677Biological/Vaccine: Allogeneic HB-adMSCs1件: Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins---1件: 6
678Biological: Benralizumab, Biological: Placebo to Mepolizumab2件: Benralizumab,
Mepolizumab		2件: D04923 ,
D09874 		2件: IL5,
IL5RA 💬		13件: Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬1件: 44
679Biological: Etanercept and its biosimilars1件: Etanercept1件: D00742 2件: LTA,
TNF 💬		67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 271
680Biological: Kiovig® (Human normal Immunoglobulin for intravenous administration 100mg/mL)1件: Human immunoglobulin G---1件: 14
681Biological: Mepolizumab, Biological: Placebo to Benralizumab2件: Benralizumab,
Mepolizumab		2件: D04923 ,
D09874 		2件: IL5,
IL5RA 💬		13件: Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬1件: 44
682Biological: mesenchymal stem cell----1件: 93
683Biological: SM03----1件: 46
684Biological: Umbilical Cord Based Allogenic Mesenchymal Stem Cell----1件: 113
685Biologically active human fecal microbiota----1件: 97
686Biologics----1件: 46
687BION-1301 Multiple Doses----1件: 66
688BION-1301 Single Dose----1件: 66
689BIOOPA dressing----1件: 36
690Biopsies----1件: 97
691Biopsy----4件: 19, 51, 78, 193
692Biopsy of the labial salivary gland----1件: 53
693Biosimilar----4件: 46, 96, 97, 271
694Biosimilar adalimumab1件: Adalimumab1件: D02597 1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 107
695Biosimilar Etanercept1件: Etanercept1件: D00742 2件: LTA,
TNF 💬		67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 107
696Biosimilar Infliximab1件: Infliximab1件: D02598 1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬3件: 46, 96, 97
697Biosimilar product to adalimumab1件: Adalimumab1件: D02597 1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 46
698Biospecimen Collection----2件: 97, 159
699BioStamp nPoint device----1件: 8
700Biostate----1件: 288
701Biostate®----1件: 288
702BIOTIN1件: Biotin1件: D00029 --5件: 2, 8, 10, 13, 20
703Biotina1件: Biotin1件: D00029 --2件: 8, 13
704BIRB 796 BS, high dose----1件: 46
705BIRB 796 BS, low dose----1件: 46
706BIRCH BARK EXTRACT1件: Birch bark extract---1件: 36
707BIRT 2584 XX----1件: 13
708BIRT 2584XX----1件: 13
709BIRTAMIMAB1件: Birtamimab1件: D11373 --1件: 28
710BIS-CHOLINE TETRATHIOMOLYBDATE2件: Choline,
Tetrathiomolybdate		1件: D07690 --1件: 171
711BIS-CHOLINE TETRATHIOMOLYBDATE, bis[(2-Hydroxyethyl)trimethylammonium] tetrathiomolybdate2件: Choline,
Tetrathiomolybdate		1件: D07690 --1件: 171
712Bisacodyl1件: Bisacodyl1件: D00245 --1件: 13
713BISOPROLOL1件: Bisoprolol2件: D00634 ,
D02342 		1件: ADRB1 💬11件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬3件: 67, 86, 113
714Bisoprolol Fumarate1件: Bisoprolol2件: D00634 ,
D02342 		1件: ADRB1 💬11件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 113
715Bisphosphonate treatment----2件: 113, 299
716Bisphosphonates----2件: 6, 274
717BITTER CANDYTUFT FRESH PLANT EXTRACT----1件: 97
718Bitterschleifenblume-ganzpflanze 1,5ml/10ml----1件: 97
719BIV009----2件: 61, 162
720Bivigam----1件: 65
721BIVV001 (rFVIIIFc-VWF-XTEN)----1件: 288
722BIVV009----1件: 61
723BIVV020----2件: 14, 61
724BIVV020/SAR445088----1件: 14
725BL-7040----1件: 97
726BL-8040----1件: 60
727Bladder instillation with heparin/ lidocaine2件: Heparin,
Lidocaine		4件: D00358 ,
D02086 ,
D07510 ,
D08127 		6件: SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A,
SERPINC1 💬		4件: Adrenergic signaling in cardiomyocytes, Complement and coagulation cascades, Dopaminergic synapse, Taste transduction 💬1件: 226
728Bladder instillation WITH triamcinolone acetonide1件: Triamcinolone5件: D00385 ,
D00983 ,
D00984 ,
D00985 ,
D06216 		1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 226
729Bladder instillation WITHOUT triamcinolone acetonide1件: Triamcinolone5件: D00385 ,
D00983 ,
D00984 ,
D00985 ,
D06216 		1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 226
730Bladder Instillations----1件: 226
731Blarcamesine1件: Blarcamesine1件: D11383 6件: CHRM1,
CHRM2,
CHRM3,
CHRM4,
CHRM5,
SIGMAR1 💬		14件: Alzheimer disease, Amyotrophic lateral sclerosis, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬1件: 156
732BLD-2660----1件: 85
733Bleomycin1件: Bleomycin3件: D02177 ,
D03229 ,
D07535 		--4件: 96, 278, 279, 280
734Bleomycin + Fibrovein1件: Bleomycin3件: D02177 ,
D03229 ,
D07535 		--1件: 279
735Bleomycin Baxter1件: Bleomycin3件: D02177 ,
D03229 ,
D07535 		--1件: 279
736Bleselumab1件: Bleselumab1件: D11357 1件: CD40 💬17件: Allograft rejection, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Human T-cell leukemia virus 1 infection, Intestinal immune network for IgA production, Lipid and atherosclerosis, Malaria, NF-kappa B signaling pathway, Primary immunodeficiency, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Viral myocarditis 💬1件: 222
737BLF----1件: 299
738BLI-1300 high dose----1件: 96
739BLI-1300 low dose----1件: 96
740Blinded (Avatrombopoag tablets)----1件: 63
741Blinded CDCA 250 mg TID1件: Chenodeoxycholic acid1件: D00163 1件: NR1H4 💬1件: Bile secretion 💬1件: 263
742Blisibimod1件: Blisibimod1件: D10311 --5件: 43, 44, 49, 63, 66
743Blisibimod Injection1件: Blisibimod1件: D10311 --1件: 66
744Blokium 50----1件: 167
745BLOKIUM 50 mg comprimidos----1件: 167
746Blood----1件: 46
747Blood analysis----1件: 6
748Blood and stools samples----1件: 96
749Blood coagulation Factor VIII and vWF, human1件: Beroctocog alfa---1件: 288
750Blood coagulation factor XIII1件: Factor XIII (human)---1件: 51
751Blood collection----2件: 229, 271
752Blood Collection for PK Testing (15 Mins Before Injection)----1件: 46
753Blood Collection for PK Testing (15 minutes post injection)----1件: 46
754Blood Collection for PK Testing (18-20 hours post injection)----1件: 46
755Blood Collection for PK Testing (180 minutes post injection)----1件: 46
756Blood Collection for PK Testing (60 minutes post injection)----1件: 46
757Blood Collection for PK Testing (after injection)----1件: 46
758Blood draw----5件: 6, 19, 65, 231, 299
759Blood draw for the laboratory assessment----1件: 303
760Blood draw.----2件: 231, 299
761Blood draws----1件: 78
762Blood pressure----1件: 84
763Blood sample----18件: 8, 13, 46, 49, 51, 53, 61, 65, 66, 84, 96, 97, 107, 127, 235, 274, 288, 299
764Blood sample and environmental survey----1件: 2
765Blood sample collection----1件: 85
766Blood samples----9件: 13, 41, 46, 51, 61, 97, 227, 240, 271
767Blood sampling----6件: 13, 17, 19, 46, 51, 96
768Blood sampling before----1件: 78
769Blood sampling for determination of serum Zn----1件: 299
770Blood sampling from infant----3件: 46, 96, 271
771Blood sampling from mother----3件: 46, 96, 271
772Blood sampling from umbilical cord----3件: 46, 96, 271
773Blood sampling, endoscopy----1件: 97
774Blood test----6件: 36, 51, 86, 113, 162, 299
775Blood tests----2件: 46, 263
776BLS-M22----1件: 113
777Blue light photopheresis----1件: 96
778Blue light-absorbing sunglasses----1件: 90
779Bluefish1件: Bluefish---1件: 58
780BLZ945----1件: 2
781BM110----1件: 19
782BMDex----1件: 28
783BMMNC----1件: 13
784BMMNCs----1件: 90
785BMN 044----1件: 113
786BMN 044 IV 6 mg/kg----1件: 113
787BMN 044 IV 9 mg/kg----1件: 113
788BMN 044 SC 6 mg/kg----1件: 113
789BMN 045----1件: 113
790BMN 053----1件: 113
791BMN 110----1件: 19
792BMN 110 - Every Other Week----1件: 19
793BMN 110 - Weekly----1件: 19
794BMN 110 Every Other Week----1件: 19
795BMN 110 Weekly----1件: 19
796BMN 111----1件: 276
797BMN 165----1件: 240
798BMN 165 (rAvPAL-PEG)1件: Pegvaliase1件: D11077 1件: PAH 💬5件: Biosynthesis of amino acids, Folate biosynthesis, Metabolic pathways, Phenylalanine metabolism, Phenylalanine, tyrosine and tryptophan biosynthesis 💬1件: 240
799BMN 190----1件: 19
800BMN 250----1件: 19
801BMN 307----1件: 240
802BMN 701----1件: 256
803BMN053----1件: 113
804BMN165 20mg/day----1件: 240
805BMN165 40mg/day----1件: 240
806BMN190 recombinant human tripeptidyl peptidase-1 (rhTPP1)----1件: 19
807BMP-21件: Dibotermin alfa1件: D03779 1件: BMPR2 💬7件: Axon guidance, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Hippo signaling pathway, MicroRNAs in cancer, Signaling pathways regulating pluripotency of stem cells, TGF-beta signaling pathway 💬1件: 34
808BMS 188667 (Abatacept)1件: Abatacept1件: D03203 2件: CD80,
CD86 💬		12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis 💬1件: 13
809BMS Drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin)5件: Digoxin,
Flurbiprofen,
Midazolam,
Montelukast,
Omeprazole		13件: D00298 ,
D00330 ,
D00455 ,
D00529 ,
D00550 ,
D00696 ,
D01207 ,
D01475 ,
D02290 ,
D05028 ,
D05259 ,
D05261 ,
D08229 		25件: ATP1A1,
ATP1A2,
ATP1A3,
ATP1A4,
ATP4A,
ATP4B,
CYSLTR1,
GABRA1,
GABRA2,
GABRA3,
GABRA4,
GABRA5,
GABRA6,
GABRB1,
GABRB2,
GABRB3,
GABRD,
GABRE,
GABRG1,
GABRG2,
GABRG3,
GABRP,
GABRQ,
PTGS1,
PTGS2 💬		49件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Arachidonic acid metabolism, Bile secretion, C-type lectin receptor signaling pathway, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Chemical carcinogenesis - DNA adducts, Collecting duct acid secretion, Endocrine and other factor-regulated calcium reabsorption, GABAergic synapse, Gastric acid secretion, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Insulin secretion, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, Mineral absorption, Morphine addiction, NF-kappa B signaling pathway, Neuroactive ligand-receptor interaction, Nicotine addiction, Ovarian steroidogenesis, Oxidative phosphorylation, Oxytocin signaling pathway, Pancreatic secretion, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Protein digestion and absorption, Proximal tubule bicarbonate reclamation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Salivary secretion, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, Taste transduction, Thyroid hormone signaling pathway, Thyroid hormone synthesis, VEGF signaling pathway, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 46
810BMS-188667----9件: 46, 49, 53, 65, 96, 97, 107, 222, 271
811BMS-232632----1件: 265
812BMS-5829491件: BMS-582949---1件: 46
813BMS-582949 and Methotrexate2件: BMS-582949,
Methotrexate		2件: D00142 ,
D02115 		2件: DHFR,
DHFR2 💬		5件: Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬1件: 46
814BMS-8173991件: BMS-817399---1件: 46
815BMS-9316991件: Lulizumab pegol---3件: 49, 53, 160
816BMS-936557----2件: 96, 97
817BMS-936557 (Anti-IP-10 Antibody)----1件: 96
818BMS-9454291件: Clazakizumab1件: D10312 --2件: 46, 96
819BMS-986004----1件: 63
820BMS-986004 1500 mg IV----1件: 63
821BMS-986004 225 mg IV----1件: 63
822BMS-986004 675 mg IV----1件: 63
823BMS-986004 75 mg IV----1件: 63
824BMS-9860201件: BMS-986020---2件: 51, 85
825BMS-986089----1件: 113
826BMS-986089-01 (RO7239361) , anti-myostatin----1件: 113
827BMS-986089-01 (RO7239361) Injections, 15 mg/Syringe (21.4 mg/mL)----1件: 113
828BMS-986089-01 (RO7239361) Injections, 35 mg/Syringe (50 mg/mL)----1件: 113
829BMS-986089-01 (RO7239361) Injections, 50 mg/Syringe (71.4 mg/mL)----1件: 113
830BMS-986089-01 (RO7239361) Injections, 7.5 mg/Syringe (10.7 mg/mL)----1件: 113
831BMS-986089-01 (RO7239361), anti-myostatin----1件: 113
832BMS-986089-01 Injections, 15 mg/Syringe (21.4 mg/mL)----1件: 113
833BMS-986089-01 Injections, 35 mg/Syringe (50 mg/mL)----1件: 113
834BMS-986089-01 Injections, 50 mg/Syringe (71.4 mg/mL)----1件: 113
835BMS-986089-01 Injections, 7.5 mg/Syringe (10.7 mg/mL)----1件: 113
836BMS-986089-01, Anti-myostatin----1件: 113
837BMS-9861041件: BMS-986104---1件: 46
838BMS-9861421件: BMS-986142---3件: 46, 53, 160
839BMS-986142 200mg1件: BMS-986142---1件: 46
840BMS-986142 350mg1件: BMS-986142---1件: 46
841BMS-986165----3件: 49, 96, 97
842BMS-986165 Capsule----1件: 49
843BMS-986165 Dose 1----1件: 97
844BMS-986165 Dose 2----1件: 97
845BMS-986165 Tablet----1件: 49
846BMS-986166----1件: 97
847BMS-9861681件: Gosuranemab1件: D11293 1件: MAPT 💬4件: Alzheimer disease, MAPK signaling pathway, Parkinson disease, Pathways of neurodegeneration - multiple diseases 💬1件: 5
848BMS-986184----1件: 97
849BMS-9861951件: Branebrutinib1件: D11478 1件: BTK 💬7件: B cell receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, Primary immunodeficiency 💬3件: 46, 49, 53
850BMS-986251----2件: 46, 271
851BMS-9862561件: Afimetoran1件: D11908 --1件: 49
852BMS-986256 (Oral)1件: Afimetoran1件: D11908 --1件: 49
853BMS-986256-06, TLR7/8 Antagonist1件: Afimetoran1件: D11908 --1件: 49
854BMS-986278----1件: 85
855BMS-986325----1件: 53
856BMS188667----1件: 46
857BMS986142----3件: 46, 53, 160
858BMS986165----2件: 96, 97
859BMS986168----1件: 5
860BMS986195----3件: 46, 49, 53
861BN82451B----1件: 8
862BN8251B----1件: 8
863BNJ441----1件: 66
864BNP----2件: 46, 58
865BNP blood sample test----1件: 58
866BNT162b2----5件: 13, 35, 46, 49, 51
867Bocidelpar----1件: 113
868BodyBio Balance Oil1件: Isoxaflutole---1件: 13
869BodyBio PC----1件: 13
870Bof-, Mazelen-, Rubellavaccin, poeder voor injectievloeistof----1件: 107
871Bone balance measurements1件: Isoxaflutole---1件: 81
872Bone densitometry----2件: 49, 162
873Bone marrow ablation with stem cell support----2件: 28, 60
874Bone marrow aspiration----2件: 60, 285
875Bone Marrow Aspiration and Biopsy----1件: 28
876Bone marrow autologous mesenchymal stem cells transplantation----1件: 13
877Bone Marrow Concentrate----1件: 70
878Bone marrow derived mesenchymal stem cells----2件: 6, 60
879Bone Marrow Derived Mesenchymal Stem cells (MSCs)----1件: 96
880Bone marrow infusion----1件: 36
881Bone marrow mesenchymal stem cells----1件: 85
882Bone marrow mononuclear cells----1件: 57
883Bone Marrow MSC Derived Extracellular Vesicle Isolate----1件: 96
884Bone marrow or umbilical cord blood (UCG) stem cell transplantation----1件: 36
885Bone Marrow Transplant----2件: 60, 274
886Bone marrow transplantation----4件: 51, 60, 284, 285
887Bone marrow-derived mesenchymal stem cells----1件: 298
888Bonefos1件: Clodronic acid2件: D03544 ,
D03545 		--1件: 274
889BoNT-A----1件: 6
890Bony Toxicity----1件: 34
891BOOST cells----1件: 274
892Boost VHC----1件: 299
893Boostrix1件: Clostridium tetani toxoid antigen (formaldehyde inactivated)---1件: 46
894Boostrix®1件: Clostridium tetani toxoid antigen (formaldehyde inactivated)---1件: 46
895Boots High Strength Garlic Odour Controlled1件: Garlic1件: D12020 --1件: 299
896BORAGE OIL1件: Borage oil---1件: 13
897BORAGE OIL 20% GLA1件: Borage oil---1件: 13
898Borage seed oil----1件: 46
899BORTEZOMIB1件: Bortezomib1件: D03150 1件: PSMB5 💬8件: Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬16件: 11, 13, 26, 28, 46, 49, 51, 61, 63, 64, 66, 228, 256, 283, 288, 331
900Bortezomib (Velcade®)1件: Bortezomib1件: D03150 1件: PSMB5 💬8件: Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬1件: 66
901Bortezomib Accord2件: Bortezomib,
Bortezomib D-mannitol		1件: D03150 1件: PSMB5 💬8件: Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬1件: 28
902Bortezomib D-mannitol2件: Bortezomib,
Mannitol		2件: D00062 ,
D03150 		1件: PSMB5 💬8件: Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬1件: 28
903Bortezomib Injection1件: Bortezomib1件: D03150 1件: PSMB5 💬8件: Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬1件: 64
904Bortezomib/dexamethasone2件: Bortezomib,
Dexamethasone		10件: D00292 ,
D00975 ,
D01510 ,
D01615 ,
D01632 ,
D01948 ,
D02174 ,
D02591 ,
D02592 ,
D03150 		2件: NR3C1,
PSMB5 💬		9件: Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Neuroactive ligand-receptor interaction, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬1件: 283
905Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone2件: Bortezomib,
Dexamethasone		10件: D00292 ,
D00975 ,
D01510 ,
D01615 ,
D01632 ,
D01948 ,
D02174 ,
D02591 ,
D02592 ,
D03150 		2件: NR3C1,
PSMB5 💬		9件: Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Neuroactive ligand-receptor interaction, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬1件: 28
906BOS161721----1件: 49
907Bosentan1件: Bosentan2件: D01227 ,
D07538 		2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212
908Bosentan (Tracleer)1件: Bosentan2件: D01227 ,
D07538 		2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 51
909Bosentan 125 mg1件: Bosentan2件: D01227 ,
D07538 		2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 51
910Bosentan 62.5 mg1件: Bosentan2件: D01227 ,
D07538 		2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 51
911Bosentan administration1件: Bosentan2件: D01227 ,
D07538 		2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
912Bosentan and Sildenafil2件: Bosentan,
Sildenafil		4件: D01227 ,
D02229 ,
D07538 ,
D08514 		3件: EDNRA,
EDNRB,
PDE5A 💬		11件: Calcium signaling pathway, Melanogenesis, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
913Bosentan group1件: Bosentan2件: D01227 ,
D07538 		2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 51
914BOSENTAN MONOHIDRATO1件: Bosentan2件: D01227 ,
D07538 		2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
915Bosentan monohydrat1件: Bosentan2件: D01227 ,
D07538 		2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
916BOSENTAN MONOHYDRATE1件: Bosentan2件: D01227 ,
D07538 		2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬4件: 51, 84, 86, 88
917BOSENTAN MYLAN1件: Bosentan2件: D01227 ,
D07538 		2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 41
918Bosentan, Ambrisentan2件: Ambrisentan,
Bosentan		3件: D01227 ,
D07077 ,
D07538 		2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
919Bosutinib1件: Bosutinib1件: D03252 2件: ABL1,
SRC 💬		49件: Adherens junction, Axon guidance, Bacterial invasion of epithelial cells, Bladder cancer, C-type lectin receptor signaling pathway, Cell cycle, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Epithelial cell signaling in Helicobacter pylori infection, ErbB signaling pathway, Estrogen signaling pathway, Fluid shear stress and atherosclerosis, Focal adhesion, GABAergic synapse, Gap junction, GnRH signaling pathway, Hepatitis B, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, MicroRNAs in cancer, Mitophagy - animal, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Platelet activation, Prolactin signaling pathway, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Shigellosis, Thyroid hormone signaling pathway, Tight junction, Tuberculosis, VEGF signaling pathway, Viral carcinogenesis, Viral myocarditis, Yersinia infection 💬2件: 2, 67
920Bosutinib (anhydrous)1件: Bosutinib1件: D03252 2件: ABL1,
SRC 💬		49件: Adherens junction, Axon guidance, Bacterial invasion of epithelial cells, Bladder cancer, C-type lectin receptor signaling pathway, Cell cycle, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Epithelial cell signaling in Helicobacter pylori infection, ErbB signaling pathway, Estrogen signaling pathway, Fluid shear stress and atherosclerosis, Focal adhesion, GABAergic synapse, Gap junction, GnRH signaling pathway, Hepatitis B, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, MicroRNAs in cancer, Mitophagy - animal, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Platelet activation, Prolactin signaling pathway, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Shigellosis, Thyroid hormone signaling pathway, Tight junction, Tuberculosis, VEGF signaling pathway, Viral carcinogenesis, Viral myocarditis, Yersinia infection 💬1件: 67
921BOSWELAN----1件: 13
922Boswellia Serrata1件: Indian frankincense---1件: 13
923Boswellia Serrata Extract1件: Indian frankincense---1件: 13
924Boswellia serrata extract PS0201Bo capsules1件: Indian frankincense---1件: 13
925Boswellic acids (BOSWELAN)----1件: 13
926Botaretigene sparoparvovec----1件: 90
927Botox1件: Botulinum toxin type A1件: D00783 1件: SNAP25 💬2件: Insulin secretion, Synaptic vesicle cycle 💬6件: 2, 6, 13, 51, 149, 226
928BOTOX 100 UNITES ALLERGAN (PR1)1件: Botulinum toxin type A1件: D00783 1件: SNAP25 💬2件: Insulin secretion, Synaptic vesicle cycle 💬1件: 2
929Botox 100 UNT Injection1件: Botulinum toxin type A1件: D00783 1件: SNAP25 💬2件: Insulin secretion, Synaptic vesicle cycle 💬1件: 13
930BOTOX 100U in normal saline1件: Botulinum toxin type A1件: D00783 1件: SNAP25 💬2件: Insulin secretion, Synaptic vesicle cycle 💬1件: 226
931BOTOX 200U in normal saline1件: Botulinum toxin type A1件: D00783 1件: SNAP25 💬2件: Insulin secretion, Synaptic vesicle cycle 💬1件: 226
932Botox injection1件: Botulinum toxin type A1件: D00783 1件: SNAP25 💬2件: Insulin secretion, Synaptic vesicle cycle 💬1件: 2
933BOTOX®1件: Botulinum toxin type A1件: D00783 1件: SNAP25 💬2件: Insulin secretion, Synaptic vesicle cycle 💬1件: 13
934BOTOX® solution1件: Botulinum toxin type A1件: D00783 1件: SNAP25 💬2件: Insulin secretion, Synaptic vesicle cycle 💬1件: 51
935Botulinic toxin----1件: 36
936Botulinum A toxin----1件: 118
937Botulinum Neurotoxin----1件: 226
938Botulinum Toxin----3件: 6, 13, 149
939Botulinum toxin A1件: Botulinum toxin type A1件: D00783 1件: SNAP25 💬2件: Insulin secretion, Synaptic vesicle cycle 💬4件: 13, 51, 149, 226
940BOTULINUM TOXIN A - HAEMAGGLUTININ COMPLEX1件: Botulinum toxin type A1件: D00783 1件: SNAP25 💬2件: Insulin secretion, Synaptic vesicle cycle 💬1件: 13
941BOTULINUM TOXIN TYPE A1件: Botulinum toxin type A1件: D00783 1件: SNAP25 💬2件: Insulin secretion, Synaptic vesicle cycle 💬10件: 2, 5, 6, 7, 13, 15, 17, 70, 113, 149
942Botulinum toxin type A (Nabota®) injection into the gastrocnemius muscle1件: Botulinum toxin type A1件: D00783 1件: SNAP25 💬2件: Insulin secretion, Synaptic vesicle cycle 💬1件: 70
943Botulinum Toxin Type A 200U1件: Botulinum toxin type A1件: D00783 1件: SNAP25 💬2件: Insulin secretion, Synaptic vesicle cycle 💬1件: 13
944Botulinum Toxin Type A 300U1件: Botulinum toxin type A1件: D00783 1件: SNAP25 💬2件: Insulin secretion, Synaptic vesicle cycle 💬1件: 13
945Botulinum toxin type A infiltrations1件: Botulinum toxin type A1件: D00783 1件: SNAP25 💬2件: Insulin secretion, Synaptic vesicle cycle 💬1件: 13
946Botulinum toxin type B1件: Botulinum toxin type B1件: D02735 1件: SNAP25 💬2件: Insulin secretion, Synaptic vesicle cycle 💬3件: 2, 6, 51
947Botulinum toxin type B (2500 units / vial)1件: Botulinum toxin type B1件: D02735 1件: SNAP25 💬2件: Insulin secretion, Synaptic vesicle cycle 💬1件: 51
948Botulinum toxin type B (Myobloc)1件: Botulinum toxin type B1件: D02735 1件: SNAP25 💬2件: Insulin secretion, Synaptic vesicle cycle 💬2件: 2, 6
949Botulinum toxin(Botox)1件: Botulinum toxin type A1件: D00783 1件: SNAP25 💬2件: Insulin secretion, Synaptic vesicle cycle 💬1件: 51
950Botulinum Toxin: Xeomin1件: Botulinum toxin type A1件: D00783 1件: SNAP25 💬2件: Insulin secretion, Synaptic vesicle cycle 💬1件: 6
951Botulism Toxin Treatment----1件: 161
952Boulardii----2件: 96, 97
953Bovine intesastinal alkaline phosphatase (bIAP)1件: Alkaline Phosphatase---1件: 46
954Bovine intestinal alkaline phosphatase (BIAP)1件: Alkaline Phosphatase---1件: 97
955Bovine type I collagen1件: Bovine type I collagen---1件: 51
956Bovine-Calf Alkaline Phosphatase (BIAP)1件: Alkaline Phosphatase---1件: 97
957Bovine-Calf Alkaline Phosphatase BIAP1件: Alkaline Phosphatase---1件: 97
958BOW015----1件: 46
959BPA----1件: 88
960BPLG-003----1件: 78
961BPN14770----1件: 206
962BPR277----1件: 160
963BPR277 ointment----1件: 160
964BPR277 ointment (controlled application)----1件: 160
965BPS-314d-MR----1件: 86
966BPS-MR----1件: 86
967BPS804----2件: 172, 274
968BPX-501----3件: 60, 285, 326
969BPX-501 cells----3件: 60, 285, 326
970BPX-501 T cells----4件: 65, 284, 285, 326
971BQ123----1件: 17
972BR-DIM----1件: 49
973BR9001----1件: 46
974BR900A----1件: 46
975Brain Magnetic Resonance Imaging (MRI)----1件: 17
976Brain MRI/MRS/fMRI----1件: 19
977Brain PET scan----3件: 5, 7, 127
978BRAMICIL - 100 MG/ 2 ML SOLUZIONE INIETTABILE 10 FIALE DA 2 ML----1件: 299
979Bramitob----1件: 299
980BRAMITOB - 300 MG/4 ML SOLUZIONE DA NEBULIZZARE 56 CONTENITORI MONODOSE 4 ML----1件: 299
981Bramitob 300mg/4ml Nebuliser Solution----1件: 299
982BRAMITOB*NEBUL 28F 300MG/4ML----1件: 299
983BRAMITOB*NEBUL 56F 300MG/4ML----1件: 299
984Bramitob® administered by PARI eFlow® rapid electronic nebulizer----1件: 299
985Bramitob® administered by PARI LC® PLUS nebulizer----1件: 299
986Branaplam1件: Branaplam---2件: 3, 8
987Branebrutinib1件: Branebrutinib1件: D11478 1件: BTK 💬7件: B cell receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, Primary immunodeficiency 💬3件: 46, 49, 53
988BRAZIKUMAB1件: Brazikumab1件: D10912 1件: IL23A 💬9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬2件: 96, 97
989Brazikumab high dose1件: Brazikumab1件: D10912 1件: IL23A 💬9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬1件: 96
990Brazikumab Induction Dose1件: Brazikumab1件: D10912 1件: IL23A 💬9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬2件: 96, 97
991Brazikumab IV Infusion1件: Brazikumab1件: D10912 1件: IL23A 💬9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬1件: 96
992Brazikumab low dose1件: Brazikumab1件: D10912 1件: IL23A 💬9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬1件: 96
993Brazikumab Maintenance Dose1件: Brazikumab1件: D10912 1件: IL23A 💬9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬2件: 96, 97
994Brazikumab SC Injection1件: Brazikumab1件: D10912 1件: IL23A 💬9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬1件: 96
995Break in L-carnitine treatment1件: Levocarnitine3件: D02030 ,
D02176 ,
D04713 		--1件: 316
996Breast milk sampling----3件: 46, 96, 271
997BREDININ1件: Mizoribine1件: D01392 2件: IMPDH1,
IMPDH2 💬		3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism 💬1件: 46
998Bredinin tablet 150mg1件: Mizoribine1件: D01392 2件: IMPDH1,
IMPDH2 💬		3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism 💬1件: 46
999Bredinin tablet 50mg1件: Mizoribine1件: D01392 2件: IMPDH1,
IMPDH2 💬		3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism 💬1件: 46
1000Breelib nebulizer----1件: 86
1001Brensocatib1件: Brensocatib1件: D12120 1件: CTSC 💬2件: Apoptosis, Lysosome 💬1件: 299
1002Brensocatib 10 mg1件: Brensocatib1件: D12120 1件: CTSC 💬2件: Apoptosis, Lysosome 💬1件: 299
1003Brensocatib 25 mg1件: Brensocatib1件: D12120 1件: CTSC 💬2件: Apoptosis, Lysosome 💬1件: 299
1004Brentuximab1件: Brentuximab vedotin1件: D09587 10件: TNFRSF8,
TUBB,
TUBB1,
TUBB2A,
TUBB2B,
TUBB3,
TUBB4A,
TUBB4B,
TUBB6,
TUBB8 💬		11件: Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬2件: 49, 51
1005Brentuximab vedotin1件: Brentuximab vedotin1件: D09587 10件: TNFRSF8,
TUBB,
TUBB1,
TUBB2A,
TUBB2B,
TUBB3,
TUBB4A,
TUBB4B,
TUBB6,
TUBB8 💬		11件: Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬2件: 49, 51
1006Brepocitinib----1件: 49
1007Brepocitinib 25 mg----2件: 96, 97
1008Brepocitinib 5 mg----2件: 96, 97
1009Brepocitinib 5mg----1件: 96
1010Brigatinib1件: Brigatinib1件: D10866 1件: ALK 💬3件: Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways in cancer 💬1件: 34
1011Brimonidine1件: Brimonidine2件: D02076 ,
D07540 		3件: ADRA2A,
ADRA2B,
ADRA2C 💬		2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬2件: 13, 90
1012Brimonidine tartrate1件: Brimonidine2件: D02076 ,
D07540 		3件: ADRA2A,
ADRA2B,
ADRA2C 💬		2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬2件: 13, 90
1013Brimonidine Tartrate Posterior Segment Drug Delivery System (Brimo PS DDS) Applicator System1件: Brimonidine2件: D02076 ,
D07540 		3件: ADRA2A,
ADRA2B,
ADRA2C 💬		2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬1件: 90
1014Brineura1件: Cerliponase alfa1件: D10813 1件: TPP1 💬1件: Lysosome 💬1件: 19
1015Brivaracetam1件: Brivaracetam1件: D08879 1件: SV2A 💬1件: ECM-receptor interaction 💬2件: 149, 309
1016Brivaracetam 25 mg1件: Brivaracetam1件: D08879 1件: SV2A 💬1件: ECM-receptor interaction 💬1件: 309
1017Brivaracetam 50 mg1件: Brivaracetam1件: D08879 1件: SV2A 💬1件: ECM-receptor interaction 💬1件: 309
1018BRL-049653----1件: 46
1019Broccoli1件: Broccoli---3件: 36, 97, 299
1020Broccoli sprouts1件: Broccoli---1件: 299
1021Brodalumab1件: Brodalumab1件: D10061 1件: IL17RA 💬3件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway 💬2件: 37, 51
1022Brodalumab 210mg SC1件: Brodalumab1件: D10061 1件: IL17RA 💬3件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway 💬1件: 37
1023BROMOCRIPTINE1件: Bromocriptine2件: D00780 ,
D03165 		2件: DRD2,
PRL 💬		12件: Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway 💬2件: 6, 74
1024Bromocriptine and other dopamine agonists2件: Bromocriptine,
Dopamine		4件: D00633 ,
D00780 ,
D03165 ,
D07870 		6件: DRD1,
DRD2,
DRD3,
DRD4,
DRD5,
PRL 💬		15件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
1025Bromure d'Ipratropium1件: Ipratropium1件: D02212 5件: CHRM1,
CHRM2,
CHRM3,
CHRM4,
CHRM5 💬		13件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬1件: 86
1026Bronchial mucus collection----1件: 299
1027Bronchitol1件: Mannitol1件: D00062 --1件: 299
1028Broncho-Vaxom1件: OM85---1件: 85
1029Bronchoalveolar lavage (BAL fluid)----3件: 49, 51, 85
1030Bronchoalveolar lavage (BAL)----1件: 84
1031Bronchoalveolar lavage fluid collection----1件: 229
1032Bronchodilator Response----1件: 294
1033Bronchoscopy with BAL----1件: 299
1034Bronchoscopy with bronchoalveolar lavage----1件: 84
1035BRV 2.5 mg----1件: 309
1036BRV 25 mg----1件: 309
1037BRV 50 mg----1件: 309
1038BRX-345----2件: 2, 15
1039Bryostatin 11件: Bryostatin 1---1件: 62
1040BS01----1件: 90
1041BSF 208075----1件: 86
1042BSF 208075 or LU 208075----1件: 86
1043BT----4件: 6, 96, 97, 98
1044BT-11----2件: 96, 97
1045BT-11 (1000 mg)----1件: 97
1046BT-11 (500 mg)----1件: 97
1047BT-11 (Omilancor)----1件: 96
1048BT-11 1,000 mg----1件: 96
1049BT-11 1000mg----3件: 96, 97, 98
1050BT-11 500 mg----2件: 96, 97
1051BT-11 500mg----1件: 98
1052BT-11 Active----2件: 96, 97
1053BT051 200 mg----1件: 97
1054BT051 3200 mg----1件: 97
1055BT051 800 mg----1件: 97
1056BT051 up to 3200 mg----1件: 97
1057BT061----1件: 46
1058BT061 (CD4 monoclonal antibody)----1件: 46
1059BT063----1件: 49
1060BT090----1件: 65
1061BT524----1件: 65
1062BT595----2件: 63, 65
1063BT681----1件: 65
1064BT971----1件: 46
1065BTK Inhibitor----3件: 46, 53, 160
1066BTRX-2460401件: BTRX-246040---1件: 6
1067BTT-1023----1件: 46
1068BTT1023----1件: 94
1069BTT1023 IV Infusion 20 mg/mL, 5 mL Drug Product----1件: 94
1070BTX-A1件: Botulinum toxin type A1件: D00783 1件: SNAP25 💬2件: Insulin secretion, Synaptic vesicle cycle 💬1件: 6
1071Bucelipase alfa1件: Bucelipase alfa---1件: 299
1072Bucillamine1件: Bucillamine1件: D01809 --1件: 46
1073Buckwheat1件: Buckwheat---1件: 226
1074Bucladesine1件: Bucladesine1件: D07546 16件: PDE10A,
PDE11A,
PDE1A,
PDE1B,
PDE1C,
PDE2A,
PDE3A,
PDE3B,
PDE4A,
PDE4B,
PDE4C,
PDE4D,
PDE7A,
PDE7B,
PDE8A,
PDE8B 💬		18件: Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Olfactory transduction, Parathyroid hormone synthesis, secretion and action, Progesterone-mediated oocyte maturation, Purine metabolism, Regulation of lipolysis in adipocytes, Renin secretion, Taste transduction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 246
1075Budenofalk----1件: 96
1076Budenofalk 2mg rectal foam----1件: 97
1077Budenofalk 3mg----2件: 93, 97
1078Budenofalk 3mg gastro-resistant capsules----1件: 96
1079Budenofalk 9mg gastro-resistant granules----1件: 96
1080Budenofalk rectal foam----1件: 97
1081Budenofalk® suppositories----1件: 97
1082Budenofalk® suppositories (BUS)----1件: 97
1083Budesonid----1件: 95
1084BUDESONIDE1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬9件: 66, 93, 94, 95, 96, 97, 98, 228, 299
1085Budesonide ( Zentacort Capsules 3mg )1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 96
1086Budesonide (6 mg)1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 97
1087Budesonide (9 mg)1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 97
1088Budesonide 0.5 mg compresse orodispersibili1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
1089Budesonide 0.5 mg orodispersible tablets1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
1090Budesonide 0.5mg orodispersible tablet twice daily1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
1091Budesonide 1 mg compresse orodispersibili1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
1092Budesonide 1 mg orodispersible tablets1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
1093Budesonide 1 mg orodispersible tablets (BUL 1 mg)1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
1094Budesonide 1mg orodispersible tablet twice daily1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
1095Budesonide 2 mg orodispersible tablets (BUL 2 mg)1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
1096Budesonide 6 mg prolonged-release capsule, hard (BUX-PVII prototype)1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 97
1097Budesonide 6 mg prolonged-release capsules, hard (BUX-PVII prototype)1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 97
1098Budesonide 9 mg capsules, hard (BUX-PV)1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 97
1099Budesonide 9 mg prolonged-release capsule, hard (BUX-PVII prototype)1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 97
1100Budesonide 9 mg prolonged-release capsules, hard (BUX-PVII prototype)1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 97
1101Budesonide [0.4mg/ml] viscous suspension1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
1102Budesonide MMX1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 97
1103Budesonide MMX 6 mg Tablet1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 97
1104Budesonide MMX®1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 97
1105Budesonide MMX® 6 mg1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 97
1106Budesonide MMX® 9 mg1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 97
1107Budesonide oral suspension1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
1108Budesonide oral suspension [0.2 mg/ml]1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
1109Budesonide plus Prevacid1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
1110Budesonide-formoterol single inhaler2件: Budesonide,
Formoterol		4件: D00246 ,
D01373 ,
D05277 ,
D07990 		2件: ADRB2,
NR3C1 💬		9件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 299
1111Budesonide-MMX1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 97
1112Budesonide-MMX®1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 97
1113Budesonide-MMX® 6 mg1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 97
1114Budesonide-MMX® 9 mg1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 97
1115Budesonide-MMX™1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 97
1116Budesonide/formoterol2件: Budesonide,
Formoterol		4件: D00246 ,
D01373 ,
D05277 ,
D07990 		2件: ADRB2,
NR3C1 💬		9件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 228
1117BUET 0.5 mg----1件: 98
1118BUET 1 mg----1件: 98
1119BUET 1mg----1件: 98
1120BUET 2mg----1件: 98
1121BUL 0.5 mg----1件: 98
1122BUL 1 mg----1件: 98
1123BUMEKIZUMAB----1件: 46
1124Bumetanide1件: Bumetanide1件: D00247 1件: SLC12A2 💬3件: Pancreatic secretion, Salivary secretion, Vibrio cholerae infection 💬2件: 6, 158
1125Bumetanide white, oblong, scored tablet1件: Bumetanide1件: D00247 1件: SLC12A2 💬3件: Pancreatic secretion, Salivary secretion, Vibrio cholerae infection 💬1件: 6
1126BUPI5----1件: 53
1127Bupivacaine1件: Bupivacaine2件: D01450 ,
D07552 		5件: SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A 💬		3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬8件: 46, 51, 53, 70, 96, 168, 226, 298
1128BUPIVACAINE HYDROCHLORIDE1件: Bupivacaine2件: D01450 ,
D07552 		5件: SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A 💬		3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬2件: 46, 53
1129Bupivacaine hydrochloride 0.5% (Marcaine, Pfizer)1件: Bupivacaine2件: D01450 ,
D07552 		5件: SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A 💬		3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬1件: 46
1130Bupivacaine Injection 0.5%1件: Bupivacaine2件: D01450 ,
D07552 		5件: SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A 💬		3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬1件: 168
1131Bupivacaine, triamcinolone, and heparin (BTH)3件: Bupivacaine,
Heparin,
Triamcinolone		8件: D00385 ,
D00983 ,
D00984 ,
D00985 ,
D01450 ,
D06216 ,
D07510 ,
D07552 		7件: NR3C1,
SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A,
SERPINC1 💬		5件: Adrenergic signaling in cardiomyocytes, Complement and coagulation cascades, Dopaminergic synapse, Neuroactive ligand-receptor interaction, Taste transduction 💬1件: 226
1132Bupivacaine-Epinephrine 0.25%-1:200,000 Injectable Solution plus clonidine3件: Bupivacaine,
Clonidine,
Epinephrine		7件: D00095 ,
D00281 ,
D00604 ,
D00996 ,
D01450 ,
D02149 ,
D07552 		14件: ADRA1A,
ADRA1B,
ADRA1D,
ADRA2A,
ADRA2B,
ADRA2C,
ADRB1,
ADRB2,
ADRB3,
SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A 💬		16件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Taste transduction, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 70
1133Bupivacaine/epinephrine/dexamethasone3件: Bupivacaine,
Dexamethasone,
Epinephrine		14件: D00095 ,
D00292 ,
D00975 ,
D00996 ,
D01450 ,
D01510 ,
D01615 ,
D01632 ,
D01948 ,
D02149 ,
D02174 ,
D02591 ,
D02592 ,
D07552 		15件: ADRA1A,
ADRA1B,
ADRA1D,
ADRA2A,
ADRA2B,
ADRA2C,
ADRB1,
ADRB2,
ADRB3,
NR3C1,
SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A 💬		16件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Taste transduction, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 96
1134Bupivacaïne HCl 0,125% / Sufentanil 50 µg flacon à 50 ml1件: Sufentanil2件: D00845 ,
D05938 		1件: OPRM1 💬3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬1件: 70
1135Bupivicaine alone----1件: 298
1136Bupizenge----1件: 53
1137Bupleurum+Ginkgo1件: Ginkgo biloba---1件: 6
1138Buprenorphine1件: Buprenorphine2件: D00836 ,
D07132 		2件: OPRK1,
OPRM1 💬		3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬3件: 46, 70, 298
1139Buprenorphine Transdermal Patch1件: Buprenorphine2件: D00836 ,
D07132 		2件: OPRK1,
OPRM1 💬		3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬1件: 46
1140Bupropion1件: Bupropion3件: D00817 ,
D07591 ,
D07938 		2件: SLC6A2,
SLC6A3 💬		7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle 💬5件: 8, 18, 21, 96, 171
1141Bupropion & Citalopram2件: Bupropion,
Citalopram		5件: D00817 ,
D00822 ,
D07591 ,
D07704 ,
D07938 		3件: SLC6A2,
SLC6A3,
SLC6A4 💬		8件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Serotonergic synapse, Synaptic vesicle cycle 💬1件: 18
1142Bupropion Hydrochloride1件: Bupropion3件: D00817 ,
D07591 ,
D07938 		2件: SLC6A2,
SLC6A3 💬		7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle 💬1件: 171
1143Burlulipase1件: Burlulipase---1件: 299
1144Burosumab1件: Burosumab1件: D10913 1件: FGF23 💬11件: Breast cancer, Calcium signaling pathway, Gastric cancer, MAPK signaling pathway, Melanoma, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton 💬1件: 238
1145BUSILVEX1件: Busulfan1件: D00248 --4件: 19, 36, 60, 65
1146BUSILVEX - 6 MG/ML - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO - 10 ML 8 FLACONCINI1件: Busulfan1件: D00248 --2件: 19, 65
1147Buspirone1件: Buspirone2件: D00702 ,
D07593 		2件: DRD2,
HTR1A 💬		10件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Serotonergic synapse, Taste transduction, cAMP signaling pathway 💬3件: 6, 51, 179
1148Buspirone Hydrochloride1件: Buspirone2件: D00702 ,
D07593 		2件: DRD2,
HTR1A 💬		10件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Serotonergic synapse, Taste transduction, cAMP signaling pathway 💬1件: 6
1149Busulfan1件: Busulfan1件: D00248 --13件: 19, 20, 28, 36, 49, 51, 60, 65, 164, 274, 284, 285, 326
1150Busulfan IV1件: Busulfan1件: D00248 --1件: 65
1151Busulfan test dose1件: Busulfan1件: D00248 --1件: 65
1152Busulfan, Cyclophosphamide, Antithymocyte Globulin2件: Busulfan,
Cyclophosphamide		3件: D00248 ,
D00287 ,
D07760 		--2件: 19, 20
1153Busulfan, Cyclophosphamide, ATG2件: Busulfan,
Cyclophosphamide		3件: D00248 ,
D00287 ,
D07760 		--1件: 19
1154Busulfan, Cyclophosphamide, ATG, GCSF2件: Busulfan,
Cyclophosphamide		3件: D00248 ,
D00287 ,
D07760 		--2件: 65, 284
1155Busulfan, Cyclophosphamide, Thymoglobulin, Fludarabine (Conditioning regimen)4件: Antithymocyte immunoglobulin (rabbit),
Busulfan,
Cyclophosphamide,
Fludarabine		5件: D00248 ,
D00287 ,
D01907 ,
D07760 ,
D07966 		1件: RRM1 💬5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬1件: 326
1156Busulfan, Fludarabine and ATG2件: Busulfan,
Fludarabine		3件: D00248 ,
D01907 ,
D07966 		1件: RRM1 💬5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬1件: 65
1157Busulfan, fludarabine, & cyclophosphamide with immunosuppression with ATG and cyclosporine.4件: Busulfan,
Cyclophosphamide,
Cyclosporine,
Fludarabine		6件: D00184 ,
D00248 ,
D00287 ,
D01907 ,
D07760 ,
D07966 		6件: PPP3CA,
PPP3CB,
PPP3CC,
PPP3R1,
PPP3R2,
RRM1 💬		38件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Drug metabolism - other enzymes, Glucagon signaling pathway, Glutamatergic synapse, Glutathione metabolism, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Metabolic pathways, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Purine metabolism, Pyrimidine metabolism, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬2件: 60, 285
1158Busulfan, Fludarabine, ATG, TLI2件: Busulfan,
Fludarabine		3件: D00248 ,
D01907 ,
D07966 		1件: RRM1 💬5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬2件: 65, 284
1159Busulfan/Fludarabine phosphate/Tacrolimus/Methotrexate/G-CSF6件: Busulfan,
Filgrastim,
Fludarabine,
Methotrexate,
Phosphate ion,
Tacrolimus		8件: D00107 ,
D00142 ,
D00248 ,
D01907 ,
D02115 ,
D03235 ,
D07966 ,
D08556 		9件: CSF3R,
DHFR,
DHFR2,
PPP3CA,
PPP3CB,
PPP3CC,
PPP3R1,
PPP3R2,
RRM1 💬		47件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Antifolate resistance, Axon guidance, B cell receptor signaling pathway, Biosynthesis of cofactors, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Drug metabolism - other enzymes, Folate biosynthesis, Glucagon signaling pathway, Glutamatergic synapse, Glutathione metabolism, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Metabolic pathways, Natural killer cell mediated cytotoxicity, One carbon pool by folate, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Purine metabolism, Pyrimidine metabolism, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬1件: 60
1160BUSULFANO1件: Busulfan1件: D00248 --1件: 19
1161Butanoic acid1件: Butyric Acid1件: D05866 --3件: 34, 51, 97
1162Butylphthalide1件: Butylphthalide---4件: 2, 6, 18, 22
1163Butyrate1件: Butyric Acid1件: D05866 --2件: 97, 291
1164Butyrate enemas + routine management1件: Butyric Acid1件: D05866 --1件: 291
1165BUU 0.4mg/ml----1件: 98
1166BVS857----1件: 1
1167BX-1----1件: 13
1168BX004-A----1件: 299
1169By demand----2件: 96, 97
1170BYDUREON1件: Exenatide1件: D04121 1件: GLP1R 💬3件: Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬2件: 6, 17
1171Bydureon 2 mg powder and solvent for prolonged-release suspension2件: Exenatide,
Manganese citrate		1件: D04121 1件: GLP1R 💬3件: Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 6
1172Byetta1件: Exenatide1件: D04121 1件: GLP1R 💬3件: Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬3件: 6, 78, 193
1173Byetta 5 micrograms1件: Exenatide1件: D04121 1件: GLP1R 💬3件: Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 6
1174BYM338----1件: 15
1175BYM338 (Bimagrumab)1件: Bimagrumab1件: D10620 2件: ACVR2A,
ACVR2B 💬		4件: Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Signaling pathways regulating pluripotency of stem cells, TGF-beta signaling pathway 💬1件: 15
1176BYM338/bimagrumab1件: Bimagrumab1件: D10620 2件: ACVR2A,
ACVR2B 💬		4件: Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Signaling pathways regulating pluripotency of stem cells, TGF-beta signaling pathway 💬1件: 15
1177Béfizal----1件: 302